


The Journal of the American Diabetes Association

diabetes

Volume 13 • 1964

INDEX

By Subject and Author



03567

Copyright 1965, by American Diabetes Association, Inc.

© 1965
AMERICAN
DIABETES
ASSOCIATION

SUBJECT INDEX 1964

This index covers all reading matter in Volume 13 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 17.

A

ABORTIONS
and glucose tolerance, 293

ACANTHOSIS NIGRICANS, 395-399

ACETOACETATES
and β -hydroxybutyric acid, 522
and insulin deficiency, 352

ACETOHEXAMIDE, *440, *660

N-ACETYL-D-GLUCOSAMINE
and blood glucose, *549

ACHILLES REFLEX, *320, *320

ACHLORHYDRIA, *328

ACHRESTIC DIABETES, *440

ACIDOSIS
and insulin, *327

ACIDOSIS, DIABETIC
and adrenal cortical hyperfunction, *102
and amino-aciduria, 20
and emotional stress, 419-420
and serum insulin antagonist, 252

ACIDOSIS, LACTIC, *328, 615

ACIDS
deoxyribonucleic
and proteins, 452
glucuronic
and glucose metabolism, *556
and hepatic detoxication, *553
indoleacetic
and insulin degradation, 227
lactic
and glucose, 615-621
production in adipose tissue, *105
and pyruvic acid reduction, 78
linoleic
and cholesterol metabolism, 43
and phospholipids, 183
nicotinic, *441
and fatty acid metabolism, *553
and hypercholesterolemia, 568, 605
oleic
and lipogenesis, *102
palmitic
metabolism, *323
and phospholipids, 183
and pancreatic cell vacuolization, 68
para-amino-salicylic, *104

pyruvic
and glucose, 615-621
and protein-carbohydrate interconversion, 78
and thalidomide, *212

ribonucleic
and proteins, 452
and radioactive amino acid incorporation, 68

trichloroacetic
and insulin-I-131, 23

uric
and obesity, *321

ACROMEGALY
and fasting insulin-like activity levels, 510
and growth hormone, *214, 356, 457
and insulin, *216
and iodo-insulin clearance, *100

ACTH. *See* Adrenocorticotrophic hormone

ACTINOMYCIN, *445

ADDISON'S DISEASE, 169, *213

ADENOMAS
insulinoma, and multiple neurofibromatosis, *321
islet cell, *214, *660
and hypoglycemia, *217
and insulin, *662
and peptic ulcer, *328

ADENOSINE TRIPHOSPHATE
and amino acid adenylates, 452

ADRENAL GLANDS
Addison's disease
and insulin, 169-176
cortex
and adrenocorticotrophic hormone, *445
and diabetic acidosis, *102
and hypophysectomy, *101
and glucose production, 350
and hyperglycemia, 194
hyperplasia, *325
and adenoma and peptic ulcer, *328
maternal weight in insulin-treated rat, 46

ADRENALECTOMY
and benzothiadiazines, 115, 641
and diazoxide, 411
and glucose phosphorylation, 350

and plasma insulin-like activity, *439
and retinal metabolism, *213

ADRENALIN. *See* Epinephrine

ADRENOCORTICOTROPHIC HORMONE
and Addison's disease, 170
and Cushing's syndrome, *101
deficiency, *546
and diabetic pregnancy, 93
and free fatty acids, *324
and glycerol, 298
and metasomatotrophin-diabetic dog, 123
and pentose cycle, *445
and Sheehan's syndrome, 170

ADRENOCORTICOTROPIN
and epididymal fat pad tissue, 75
and two antibody immunoassay, 5

AFRICANS, EAST
and serum cholesterol, *107

AGE
and amyotrophy, 310
and glomerulosclerosis, 50
and glucose tolerance, 294
in Hiroshima, Japan, 486, 518
and pre-beta-lipoproteins, 158
and steroid-tolbutamide test, 129
and vascular and neurologic complications, *322
and Yemenite Jews, 268

AGLYCOSURIC DIABETES, *327

AGRANULOCYTOSIS
and chlorpropamide, *658

ALBUMIN
bovine serum, 1, 22
and fatty acid release, *107
and glucose uptake, *546
and insulin, *108

ALBUMINURIA
and growth hormone, 123

ALLEN, FREDERICK MADISON, 318-319

ALLOXAN
toxic effects, 78, *445

ALLOXAN DIABETES
and antiserum, 80
and carbon dioxide fixation, *108
and protein synthetic inhibitors, *445

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
March-April, 115-224

May-June, 225-338
July-August, 339-450

September-October, 451-562
November-December, 563-676

SUBJECT INDEX 1964

AMERICAN DIABETES ASSOCIATION
 Affiliate Associations, 113, 223, 333, 449, 560
 and American College of Physicians, 560
 annual meetings
 Twenty-fifth, 332, 448, 559
 Twenty-fourth, 446, 663
 business, 670
 awards
 Banting Medals, 219, 665
 Banting Memorial, 219, 663
 Lilly, 219, 448, 559, 664
 Outstanding Layman, 669
 Board of Directors, 446
 Committees on Scientific Publications and Professional Education
 Diabetes Mellitus: Diagnosis and Treatment, 331
 Committee of State Coordinators, 111
 Committee on Statistics, 312
 Constitution and Bylaws, revised, 111
 Diabetes Week, 333, 449
FORECAST
 "Dietary Fats," 449
 "Differences Between U40 and U80 Insulin," 332
 "How to Use Fat in Your Diet," 449
 "Types of Insulin," 111
 honorary membership, 669
 index, diabetes-related literature, 222
 Journal
 increased size, 94
 index, 112
 monthly publication, 448
 new title page, 95
 library facilities, lack of, 112
 in memoriam
 Allen, Frederick Madison, 318
 Bell, Elexious T., 433
 Brigham, F. Gorham, 435
 Engel, Frank Libman, 210
 National Headquarters, new address, 222
 necrology, 114, 224, 334, 450, 560
 new members, 112, 222, 333, 449, 559
 News notes, 113, 224, 333, 450, 560
 officers, 446
 organizational meetings, 218, 330
 personals, 114, 224, 334, 450, 560
 postgraduate courses, 113, 222, 331, 558
 program, 447
 Research and Essay Contests, 111, 559
 winners, 558
 research fellowships, 332, 449
 scientific exhibit, 332
 and survey of therapy, 472-478
 third research symposium, 222, 330, 446
AMINO ACIDS
 and blood glucose, 227
 free
 transplacental gradients, *100

in insulin, 135, 340
 and maternal toxemia, *100
 nitrogen, and glucagon, *551
 and proteins, *445, 452
 in serum, 16

AMINOACIDURIA
 and disaccharide intolerance in infants, *321
 and tolbutamide, 19

AMINOPYRINE, *322

AMPUTATIONS
 and arteriosclerosis obliterans, 366, *550
 below-knee, *546

AMYOTROPHY, DIABETIC, 308, 541

ANEMIA, PERNICIOUS, *328

ANGINA PECTORIS, *548

ANGIOPATHY, 482
 and insulin-antibody complexes, *214
 and pancreatic diabetes, 315-316

ANTAGONISTS. See also Antibodies
 to insulin, 225-259, 339-365
 circulating, 261
 hormone, 248, 362-365
 insulinase, 226, 248
 in plasma, 247-259
 synalbumin, 241-246

ANTIBODIES
 gamma globulin, 177, 250
 to glucagon, 563
 inhibitor, 1-5
 to insulin, 12, *106, 136, 248, 261, 634
 bovine, *102
 -like activity, *324
 placental transfer, *441
 precipitating, *214
 and pregnancy, *327
 and thiazide diuretics, *103, 639
 species-specific, 22-29, 136

ANTISERUM
 horse, to beef insulin, 26
 and insulin-I-131 degradation, 23

ARGYLL ROBERTSON PUPIL, 307

ARTERIOSCLEROSIS
 and amputation, 370
 among diabetic Yemenite Jews, 270
 and hyperlipemia, *101

ARTERIOSCLEROSIS OBLITERANS
 and ischemia of lower extremity, *549

ARTHROSIS, RHEUMATOID
 and diabetic retinopathy, *554

ASTHMA
 and steroid administration, *103

ASTWOOD'S PEPTIDE I, *438

ATHEROMA
 and cholesterol, *102

ATHEROSCLEROSIS, 87, 90, 482
 and diet, 43, *105
 and lipids, *556
 in lower-limb arteries, *661
 and serum triglycerides, 425
 and sodium chloride, 70

ATOMIC BOMB CASUALTY COMMISSION, 485, 518

AUTOANALYZER TEST, 30, 177, *327, 409, 533, 601

AUTORADIOGRAPHY
 and cobalt location, 401
 of insulin distribution, *557

AZOTEMIC PSEUDODIABETES
 and intravenous sodium tolbutamide test, 33

B

BARBITAL
 and hyperglycemia, *327

BASEMENT MEMBRANE
 thickening, *660
 and protein metabolism, 458

BELL, ELEXIOUS T., 433

BENEDICTINE MONKS, 296

BENZOTHIADIAZINES, *328, *328, *438
 diabetogenicity, *443, *557, 639-644
 and hyperglycemia, 115-121, 203-204

BENZYDROFLUMETHIAZIDE, 116

BENZYL PENICILLIN G, *659

BIGUANIDES
 and unstable diabetes, *102

BLOOD
 bromsulphthalein content, 533
 and cerebrospinal fluid separation, *658
 cholesterol, 296
 chylomicron count, 291
 fructose, 77
 insulin, 190
 by isotope-immunoassay, *321
 ketones, 38
 and free fatty acid elevation, 518-526
 lipids
 and exercise, *440
 and radioactivity incorporation, *320
 studies, 154
 oxygen saturation test
 Brinkman hemoreflecter, 533
 portal venous
 and arterial hypotension, *108
 proteins
 Schenck method, 195

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
 March-April, 115-224

May-June, 225-338
 July-August, 339-450

September-October, 451-562
 November-December, 563-676

SUBJECT INDEX 1964

BLOOD GLUCOSE
 and amino acids, 227
 arterial-venous differences, 39
 and carbon dioxide fixation, *108
 and chlorothiazide, *439
 and chlorpropamide, *323
 and cobalt, 405
 and cortisol, *99
 and cortisone, 55
 and cystic fibrosis, *554
 and diazoxide, 409
 fasting
 and diethylstilbestrol, 380
 and estradiol benzoate, 380
 and fasting insulin, 179
 and hydrocortisone, 384
 in metasomatotrophin-diabetic dog, 123
 and obesity, 286-290
 and ovulatory suppression, 379
 and steroid-tolbutamide test, 128
 and tolbutamide tests, 31
 fetal, 47
 and free fatty acids, *212
 and Freund's adjuvant, 22
 and fructose, 77, *105
 and galvanic skin reflex, 601
 and glucagon, *106, 138, 565, 645
 and glucose uptake, 7
 and growth hormone, 61, 355-361
 homeostasis, 198-202
 and insulin, 24, 473
 activation, 230
 after hypophysectomy, *551
 and leucine, *213
 maternal
 and beta cells in fetal islets, 75
 and oral galactose load, *214
 and pancreatectomy, 37-43
 and pregnancy, 279
 in premature infants, *104
 of pup of insulin-treated rat, 45
 and stress, 83
 tests, 473
 AutoAnalyzer, 38, 177, *327, 409,
 533, 601
 Bertrand method, 195
 Folin-Malmros method, 71
 glucose oxidase method, 409, 502,
 519
 glucostat micromethod, 116
 Hoffman method, 154, 601
 modification of, 533
 Hugget and Nixon procedure, 502
 Nelson-Somogyi, 145, 378, 409
 modification by King and Natelson, 44
 prednisolone glucose tolerance, 575
 Somogyi-Nelson, 87, 127, 169, 287,
 291, 502, 510
 and tissue-active insulin, *324
 and tolazamide, *216
 and tolbutamide, *321
 and urinary sugar, 197, *327

BLOOD GROUPS
 and genetic factors, 184

BLOOD PRESSURE
 and arterial disease, 82, 368
 and diazoxide, 412
 and hypoglycemia, *108
 and polyneuropathy, 310

BLOOD SUGAR, 193-198
See also Blood glucose
 and anabolic steroids, *556
 and diazoxide, *658
 and tolbutamide, *661

BLOOD VESSELS
 aorta
 abdominal, calcification, 270
 and glucose utilization, *329
 and phospholipid synthesis, 182-188,
 205
 capillaries
 glomerular, in metasomatotrophin-diabetic dog, 125
 wall thickening, *546
 disease
 and electromyograms, 482
 and steroid-tolbutamide test, 131
 pancreatic veins
 insulin-like activity, *551
 peripheral
 arterial, disease, 366-372
 in Yemenite Jews, 270
 retinal
 electron microscopy of, *108
 and fluorescein leakage, *554
 small
 abnormalities, 90
 and chylomicron count, 291-296

BODY
 finger and toe
 plethysmograms, 480
 lower extremities
 and atherosclerosis, *661
 complaints, 366
 seminal vesicles and vasa deferentia,
 *553

BOOK REVIEWS
 Aceton bis Zucker (Aceton to Sugar),
 Nachschlagebuch für Zuckerkranken (A Reference Book for Diabetics), by G. Katsch, Mohnike, and H. J. John, 655
 L'Acidocétose Diabétique, by Alain Larcan and Paul Vert, 95
 Ambulatory Medical and Social Care for the Diabetic Patient (Ambulante Betreuung und Fürsorge bei Zuckerkrankheit), by A. Kaeding, 316
 Annual Review of Biochemistry, edited by J. Murray Luck, 209
 Atherosclerosis: Mechanisms as a Guide to Prevention, by Campbell Moses, 431
 Clinical Diabetes Mellitus, edited by Max Ellenberg and Harold Rifkin, 95

Clinical Endocrinology, by T. S. Danowski, 96
 Clinical Metabolism of Body Water and Electrolytes, edited by J. H. Bland, 431
 Counseling in Medical Genetics, by Sheldon C. Reed, 209
 Diabetes as a Way of Life, by T. S. Danowski, 655
 Diabetic Neuropathy (Die diabetische Neuropathie), by Albert Bischoff, 318
 Eat, Drink and Lower Your Cholesterol, by Frederick T. Zugibe, 432
 The Functional Pathology of Disease, by Arthur Grollman, 210
 Fundamentals of Diabetic Management, by James M. Moss, 97
 A Guide for the Diabetic, by S. S. Ajgaonkar, 542
 The History of Diabetes Mellitus, by N. S. Papaspyros, 542
 Konjunktivalkarrene ved Diabetes Mellitus, by Jørn Ditzel, 97
 Manual of Clinical Nutrition, by Robert S. Goodhart and Michael G. Wohl, 543
 A Manual of Diabetes for the House Officer, by William T. Nunes, 656
 Metabolic and Endocrine Physiology: an Introductory Text, by Jay Tepperman, 98
 Neuroendocrinology, by Ernst and Berta Scharrer, 656
 Nutrition in Health and Disease, by L. F. Cooper, E. M. Barber, H. S. Mitchell, H. J. Rynbergen, and J. C. Greene, 543
 Peripheral Circulation in Man, by Medical Department, The British Council, 316
 Progress in Diabetes Research, edited by K. Oberdisse and K. Jahnke, 543
 Selected Papers of Charles H. Best, by Charles H. Best, 317
 Die Zuckerkrankheit, by F. Bertram and H. Otto, 545

BRAIN
 glucose and glucagon, 565
 and lipids formation, 592-599
 metabolism
 and coma, *322
 and hexose monophosphate shunt, 585-591

BRIGHAM, F. GORHAM, 435

BRINKMAN HEMOREFLECTOR, 533

BZ-55. *See* Carbutamide

BZD. *See* Benzothiadiazines

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
 March-April, 115-224

May-June, 225-338
 July-August, 339-450

September-October, 451-562
 November-December, 563-676

C

CALCIUM transport and sodium, *103

CALORIES, *439 and atherosclerosis, 426

CANADIAN DIABETIC ASSOCIATION, 462

CARBOHYDRATES and atherosclerosis, 425 and fasting, *100 and fetal nutrition, 47 and hyperthyroidism, 194 and insulin, *324 and intravenous sodium tolbutamide test, 33 and ischemic heart disease, *557 and low protein diet, 571 metabolism and cortisol, *99 and obesity, 286 protein-bound, *657 reserves in infants, *444 and serum lipids, *661 tolerance and diabetic pregnancy, 92 and insulin, 6, 15 and pancreatitis, *100 and plasma insulin, 180 and synalbumin antagonism, 243 and thiazide diuretics, *211

CARBON DIOXIDE fixation, *108

CARBUTAMIDE and Addison's disease, *213 and metasomatotrophin-diabetic dog, 123 and plasma protein, 14 and serum lipids, *327

CARCINOMA bronchogenic, and glucagon, 566 hepatic, *215, *215 with hypoglycemia, polycythemia, and hypercalcemia, *212 pancreatic, 33, *660

CARDIOVASCULAR DISEASE. See also Heart disease among diabetic Yemenite Jews, 269 and psychosocial forces, 302

CARTILAGE powder and diabetic wounds, *658

CASE REPORTS diabetes mellitus and insipidus, *216, *557 diabetic acidosis and emotional stress, 419-420 diabetic coma without ketoacidosis, *437 diabetic steatorrhea, *557

emaciation and hypoglycemia in diabetic, *215 fat embolism in diabetes mellitus, *101 fatal diabetic glomerulosclerosis after pancreatectomy, *658 functioning islet cell adenoma, *660 generalized glycogen storage disease, *325 glaucoma and water drinking tests, 162 hepatoma with hypoglycemia, polycythemia, and hypercalcemia, *212 hypoglycemia, growth retardation, and growth hormone deficiency, *441 idiopathic hemochromatosis, *215 idiopathic infantile hypoglycemia, *439 insulin resistance and acanthosis nigricans, 395 insulinoma and multiple neurofibromatosis, *321 islet-cell adenoma and juvenile hyperinsulinism, *217 Laennec's cirrhosis and malnutrition and tolbutamide, *437 necrobiosis lipoidica diabetorum of the scalp, *548 pain in left upper quadrant of abdomen, *660 pancytopenia with tolbutamide therapy, *212 postalcoholic hypoglycemia versus islet cell tumor, *551 pulmonary infiltration with eosinophiles caused by chlorpropamide, *546 renal cortical necrosis, diabetes, and pregnancy, *327 sickle-thalassemia and fructosuria, *104 sites of occlusion with amputation, 368 spontaneous diabetes mellitus in a dog, 492-499 tolbutamide-induced hypoglycemia, *101

CATARACTS in hyperphagic monkeys, *103

CATECHOLAMINES and triglyceride breakdown, 363

CELIAIC DISEASE, *326

CEREBELLUM stimulation, and insulin, *439

CEREBRAL DYSRHYTHMIA and narcolepsy and hyperinsulinism, *326

CHILDREN achievement tests, 303 assay of insulin in plasma, 177 and cortisone-glucose tolerance test, 569-571 enzyme in leukocytes, *325 and fecal sugar, *324 and glomerulosclerosis, *216 and growth hormone deficiency, *441

and hypoglycemia, *217 and intraocular pressure, 161-163 and ketone bodies, *442 and nephropathy, *107, *216 and polyuria, *216 and pre-beta-lipoprotein, 153 and tolbutamide, *554

CHLOROTHIAZIDE, 116, *438 and diazoxide, *328 and insulin antibodies, *103 and pregnancy, *439

CHLORPROPAMIDE, *436, 473, *547, *548 and agranulocytosis, *659 and eosinophiles, *546 and insulin, *323 and lipid and glucose levels, *657 and liver function, *659 long-term therapy, *548 and perinatal mortality, *325 and plasma triglycerides, 88

CHLORTHALIDONE, 116 and carbohydrate tolerance, *211

CLINISTIX, 83, *101, *327, 502

CHOLESTEROL alpha and beta fractions, 274 and P-amino salicylate, *102 and arterial phospholipids, 187, 206 and atherosclerosis, 426 and diet, *105, *217 and fatty acids, *107 linoleate levels, *102 in Yemenite Jews, 273 metabolism, 43 and myocardial infarcts, 43 and psychosocial forces, 296

CHOLESTROLEMA, 294

CHROMATOELECTROPHORESIS and antibodies to beef insulin, 26 of insulin-I-131 dissolution from antibody, 24

CHROMATOGRAPHY and amino acid estimation, 15 and antibody and free human growth hormone, 356 gas-liquid, *212 and insulin antibodies, 635 and phosphatide separation, 183 of radioactivity incorporation, *320

CHROMIUM, TRIVALENT and glucose tolerance, 202

CHYLOMICRON in mothers of big babies, 291-296

CIRCULATION and exercise, 41 and hyperglycemia and hyperkalemia, *321 micropools, and glucose tolerance, 293 and therapeutic insulin coma, *322

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

SUBJECT INDEX 1964

COBALT
in pancreatic islet tissue, 400-407

COMA
and cerebral blood flow, *322

COMA, DIABETIC
and fatty acid synthesis, *320
without ketoacidosis, *437
and mortality, 375
and suppressible insulin-like activity, *324

COMMITTEE ON THE USE OF THERAPEUTIC AGENTS
clinical evaluation of drugs, 429

CONTRACEPTION
norethynodrel with mestranol, 378-382

CORTICOSTEROIDS
dosages, *103

CORTISOL
and amino acids, *445
and carbon dioxide fixation, *108
and glucose
metabolism, *106
phosphorylation, 350
and glycerol, 298
metabolism, *99, *102
protein-bound in pregnancy, 93

CORTISONE
and alloxanized rabbits, 55
and endocrine disorders, *101
and glomerulosclerosis in children, *216
and gluconeogenesis, 350
-glucose tolerance tests, 191, 569-571

CUSHING'S DISEASE
and pituitary irradiation, *105

CUSHING'S SYNDROME
and insulin, *101, 363

CYSTEINE
and cobalt, 405

CYSTIC FIBROSIS, *554

D

DANISH TWIN REGISTRY, *104, *214, *325

DBI. See Phenethylbiguanide

DEAE. See Selectacel ion exchange cellulose

DEMEDIULLATION
and benzothiadiazines, 115

2-DEOXYGLUCOSE
and insulin, *325

DESOXYCORTICOSTERONE ACE-TATE, 169, *213

DIABETES CONFERENCES, *437

DIABETES FAIR, *217

DIABETES INSIPIDUS, *216
nephrogenic, *557
and optic atrophy, *438

DIABETES MELLITUS
and Achilles reflex, *320
and achlorhydria, *328
and Addison's disease, *213
age at onset, 463
and intellectual and academic functioning, 304
alloxan-induced
and cartilage powder, *658
and diet, *438
and fatty acids biosynthesis, *320
and glucose metabolism in aorta, *329
and hepatic enzyme activities, 78-82
and hypophysectomy, *101
and leucine incorporation, 455
and parathyroid glands, *325
and retinal metabolism, *213
and atherosclerosis, 205, 482
and benzothiadiazines, 203-204, *438
and benzylpenicillin G, *659
and blood groups, 164-168
and chlorpropamide, *657
chronic
and beta cell degranulation, 68
and insulin-resistant, *213
complications
and synalbumin antagonism, 243
control
and exercise, 40
and glomerulosclerosis, 51
detection, *217, 381
in Europe, 192
diet and serum lipids, 425-428
duration
and cholesterol, 275
and longevity, 373-377
and peripheral arterial disease, 368
among Yemenite Jews, 268
early diagnosis, 191
electromyographic study, 479-484
and enzymes, 457
and fat embolism, *101
and glucagon, *552
in hyperphagic monkeys, *103
and hypertriglyceridemia, 87
and insulin, *99, 230-240, *553
juvenile
adjustment problems, 649
and exercise, *440
and fasting, *212
and heredity, *438
and indoleacetic acid, 228
insulin-like activity, *107, 512
and school achievement, 303-306
laboratory procedures, 191
and lactate excretion, *211
and lactic acid, 615-621
latent, 92
in cortisone-alloxan treated rabbits, 54

and steroid-tolbutamide test, 128
treatment, 192

management
and insulin deficiency, *555
and insulin-I-131, *657
during pregnancy, *439

maternal
and congenital malformations, 93, *215, *554
and fetal survival, *105, *439
and insulin content of fetal islets, 73
and Protamine Zinc Insulin, 44
and size of infants, 291
and toxemia, *100

maturity-onset
and benzothiadiazines, 204
and hyperglycemic stress, 6-12, 248
and indoleacetic acid, 228
and microangiopathy, 90-91, *546
mortality, 29
and narcolepsy and hyperinsulinism, *326
and nephropathy in childhood, *107
neurologic complications, *215, *322
and nicotinic acid, *441
oral sodium tolbutamide test, 30-36
and pancreatitis, *657
parental, and predisposition in children, 569-571

peripheral nervous system, 307-311
and pernicious anemia, *328
and phagocytosis, 424

potential, 154

practice and theory, *438

and pre-beta-lipoproteins, 153-160

and pregnancy, 91-94, *100
psychological factors, *108
and pyruvate excretion, *211
and pyruvic acid, 615-621

regulation
and glomerulosclerosis, 49-53

and serum enzymes, *553
sex differences, *441
sex distribution
in Hiroshima, Japan, 486, 518
spontaneous in dog, 492-499

statistics
Canada, 468
Japan, 485-491
United States, 312-314

and sulfisoxazole, *659

survey
England and Wales, *101
United States, *211, 472-478

symposium in Geneva, 189-192

and synalbumin antagonist, 242

treatment, *215, 472-478
with acetohexamide, *660
clinical evaluation of drugs, 429
oral, *108, *436
with sulfonylureas, 14-20
and tryptophan metabolism, *106

in twins, *104

untreated, 177
and insulin-like activity, *107
"wet tail" in hamsters, 49

among Yemenite Jews, 268-272, 273-277

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
March-April, 115-224

May-June, 225-338
July-August, 339-450

September-October, 451-562
November-December, 563-676

DIABETES, PANCREATIC
and vascular disease, 314, 479

DIABETIC SYNDROME, *547

DIARRHEA
dietary restriction, *99

DIAZOXIDE
and carbohydrate metabolism, 408-418
diabetogenic activity, 203, *557
and hyperglycemia, 115, *445, 639-644, *658

DCB
I - (2', 4' - dichlorophenyl) - 2 - t - butylaminoethanol, *440

DIET
and adult obese diabetics, 87 ✓
and atherogenesis, *438 ✓
and atherosclerosis, *105 ✓
carbohydrate
and cholesterol, *217
free, *99
cholesterol
esters, *102
and serum fatty acids, *107
and diabetes control, *102
and electrolyte excretion, *100
and exercise, 37
fatty acids, *661
and glucose
-adenosine triphosphate phosphotransferases, *443
tolerance, 30, 202, *547
and hepatic insulinase activity, 226
high carbohydrate, 287
and partially pancreatectomized dogs, 61
high fat
and atherosclerosis and thrombosis, 43
and retinopathy, 489
and ischemic heart disease, *557
and juvenile diabetics, *213
and liver necrosis, 202
low carbohydrate
and oral glucose tolerance, 286
low protein
and carbohydrates, 571
and myocardial infarcts, 70
and psychosocial forces, 296
and serum lipids, 425-428
sucrose restriction in diarrhea, *99
and tolbutamide, 14-20
vitamin B₆ deficiency, and metabolism, *549

DIETHYLDIESTROSTROL, 380

DIHYDROERGOTAMINE, *322

DOWN'S SYNDROME CHROMOSOME, *212

DRUGS
clinical evaluation, 429

E

ELECTROCARDIOGRAPHY
and hyperkalemia, *217

ELECTROPHORESIS
of cholesterol fractions, 273
and insulin mobility, 234, 253
of lipoproteins
Salt and Wolff method, 154
LKB-Productor AB, 579
of pancreatic fractions, 387
paper
insulin-antibody reaction, 1, 635
serum lipids, 273
and saccharide identification, *216
serum protein, 378

EMBOLUS, FAT, *101

ENDOCRINE GLANDS
disorders, *101

ENGEL, FRANK LIBMAN, 210

ENOVID. See Norethynodrel

ENZYMIC SYSTEM
and phospholipid synthesis, 182-188

ENZYMES, *553
activity test, *99
and alloxan, *445
dependent and independent, *548
and gluconeogenesis, 78
and glucose-6-phosphate, *443, *443, *443, *443
glutamine synthetase activity, *438
and glycogen synthesis, *217
and glycolysis, *107
hepatic activities in diabetic rats, 78-82
and hereditary fructose intolerance, 77
and insulin, 351
reduction, 226
malic, and glucocorticoids, *326
and protein synthetic inhibitors, *445
pyridinucleotide, and metabolic disturbance, 81
and pyrophosphate, 453
and visceral lesions, *658

EPINEPHRINE, *321
anti-insulin activity, 362
and diet, *436
and fatty acids, *106, *324
and glucagon, 172, *555
and growth hormone, 358
and glycerol, 298, *550
and histamine release, *662
hydrochloride, 409
and hyperglycemia, 194, *321, *551
as insulin antagonist, 257
and myocardial response, *442
and plasma corticosterone, *439
and potassium, *322

ERYTHROCYTES
glycolysis, and uremic metabolites, *552

ESTRADIOL BENZOATE, 380

ESTROGENS
and glucose tolerance, 380
and hydrocortisone, 383

ETHANOL
and hypoglycemia, *102

ETHIONINE, *445

N-ETHYLMALEIMIDE, *328
and palmitate incorporation, 184

N - ETHYL - N - HEXAHYDROBENZYLCHLOROETHYLAMINE, *322

EUROPE
diabetes detection programs, 192
Symposium on diabetes mellitus in Geneva, 189-192

EXERCISE
and blood glucose, 37-43
and blood lipids, *440
and fat oxidation, *325
and human growth hormone, 359
and lactic acid infusion, *549

EYE
opacities, in metasomatotrophin-diabetic dog, 124
pressure, 161-163

F

FAMILY HISTORY, 462-471
and carbohydrate-induced lipemia, *662
of endocrine adenomatosis, *444
glucose tolerance, *107
and ovulatory suppression, 378
and insulin resistance, 396
obesity, and benzothiadiazines, *328
and pregnancy, 291
and glucose tolerance, 281, 572
and steroid-tolbutamide test, 128
and synalbumin antagonism, 243

FATIGUE
and diet, *100

FATTY ACIDS
and carbohydrate deficit, *104
and cholesterol, *107
and diabetic coma, *320
free
under anaerobic conditions, *324
and anti-insulin serum, 299
composition, *549
and cortisol, *99
and diabetic tissues, *100
and epinephrine, 351, *550
and fasting in obesity, 286-290
and glucose loading, *326
and insulin, *212, *550, *557
and isoproterenol and DCB, *440

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
March-April, 115-224

May-June, 225-338
July-August, 339-450

September-October, 451-562
November-December, 563-676

SUBJECT INDEX 1964

and nicotinic acid, *553
and norepinephrine, 518-526
and peptide hormones, 423
sex differences, *441
after smoking, *555
and tolbutamide, 191
uptake by rat liver, *320
and glucagon, *106
and growth hormone, 363
and lipogenesis, *102
metabolism, *323, *553
nonesterified
and diet, *99
and glucose uptake, 512
and pregnancy, 291
and phospholipids, 185
and radioactivity incorporation, 594
release by perfused adipose tissue, *107
synthesis
and insulin, 351
by tissue, *443

FERTILITY
in Denmark, *104, *214, *325

FETUS
and diabetic pregnancy, 92
femoral epiphysis, 94
and hypoglycemia, 47
and insulin
antibodies, *327
degradation, 263
in rat islets, 71-77
and maternal diabetes, *105, *217
weight, and tolbutamide, 528

FLORIDA
Camp Immokalee, 645

FLUMETHIAZIDE, 116

FOOD
intake, and cortisol, *99
and jejunal motility, *102

FRUCTOSE
hereditary intolerance, 77
and insulin, *326
and metabolic acidosis, *105
and metabolism, *657
and pancreatic stimulation, *325
and sodium transport, *661

FRUCTOSE-1,6-DIPHOSPHATASE
and puromycin, 457

FRUCTOSE - DIPHOSPHATE - PHOSPHATASE, 350

FRUCTOSE - 6 - PHOSPHATE, *326

FRUCTOSEMIA
aldolase deficiency, *105

FRUCTOSURIA
hereditary, 77
nonalimentary, *104

G

GALACTOSE
and insulin, *325
oral tolerance test, *214
GALACTOSE-I-C-14, *440
GALACTOSE - I - PHOSPHATE URIDYL - TRANSFERASE, *212
GALACTOSEMIA
congenital, and microdiffusion test, *440
and Down's syndrome, *212
and fructosemia, *105
GALVANIC SKIN REFLEX
and insulin, 600-605
GASTRIC SECRETION
and glucagon, *100, *102
GASTROINTESTINAL TRACT
and glucagon, *660
pH effect, *103

GENES, *64, 462-471
and diabetic pregnancy, 92
and insulin inhibitor, *555
and microangiopathy, *658
and mortality, *214, *325
and predisposition in children, 569
and synalbumin antagonism, 243

GLAUCOMA
and water drinking provocative test, 162

GLOMERULOSCLEROSIS
and basement membrane lesions, *322
in children, *216
and diabetes regulation, 49-53
and pancreatectomy, *658

GLUCAGON, *552
and adrenal insufficiency, 174
and alcohol hypoglycemia, *103
assay
with liver adenyl cyclase, *660
Unger, Eisentraut, McCall and Madison method, 388
and blood glucose, 200
dosages, 645
and epinephrine, *555
and fatty acids, *106, *320
and glycerol, 298
and growth hormone, 358
and histamine-induced gastric secretion, *100
and insulin, 387-394
and intestinal motility, *102
and myocardial contractility, *442
and pancreatic islet tissue, *107
physiologic role, 563-568
and potassium, *322
and P-32 orthophosphate, 612

and splanchnic glucose production, *551
and starvation, *108
tolerance tests, 170
zinc, and idiopathic hypoglycemia, *439

GLUCOCORTICOIDS
and insulin action, 349-354
and lactic and pyruvic acids, 615
protein catabolic action, 351

GLUCOKINASE, *555
and glucose-6-phosphate, *322
and glycogen synthesis, *216, *217
and insulin, *444

GLUCONEOGENESIS
and adrenal cortical steroids, *444
and insulin, 351

GLUCOSE
absorption and pH, *103
and alcohol hypoglycemia, *103
carrier transport in membranes, *658
and chloropropanide, *657
and creatinine, *554
and free fatty acids
in red blood cell, *326
after smoking, *555
and glucokinase, *216
and growth hormone, *550
and hydrocortisone, *552
and hyperglycemia, 11
and hypoglycemia, idiopathic infantile, *439
and insulin, *215, *321, *324, 349
intravenous, and glucose disposal, *662
and leukemia, *103
loading, and insulin-like activity, 511
metabolism, *657

and anti-insulin serum, 532-540
and cortisol, *106
and glucuronic acid, *557
and hexose monophosphate shunt, 585-591
and histamine, *662
and metopirone, *659
and pentose cycle, *445
peripheral, *547
and tris (hydroxymethyl) aminomethane, *320
and norepinephrine, 523
oxidation in alloxan-diabetic rat, *547
and pancreatectomy, 500-508
phosphorylation in rat liver, *322
and plasma insulin-like activity, *551
and serum inorganic phosphate, *101
and sodium excretion, *329
tolerance
and diet, *547
and fasting blood glucose, *552
and glucocorticoid therapy, 350
oral, *660
and ovulatory suppression, 378-382
tolerance tests
and cortisol, *99
and glucose-C-14 disappearance rate, *211

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

intravenous, 170, 191, *216
and obesity, *556
and obstetric factors, *326
at various altitudes, *442
Nelson-Somogyi method, 55, 61
oral, 30, *101, *108, 177, 191, *326
and gingival tenderness, *212
and pregnancy, 278-285, 383-386
and starvation, 286
and pancreatectomy, 37
and plasma human growth hormone, 357
and pregnancy, 93, 281, 291, 383-386
slow, continuous infusion, 41
and trivalent chromium, 202
transport and sodium, *103, *661
in uncontrolled diabetes, 81
uptake
in anaerobic turtle heart, *107
and insulin, 251
antagonist, 94
and pituitary lipid mobilizer, *438
and uric acid, *554
utilization
in hypothermic rats, *103
and ketone bodies, *658
plasma antagonists, 251

GLUCOSE C-14
conversion to CO₂, 509-517
and glucose tolerance test, *211
incorporation and insulin, *658
and Leuconostoc mesenteroides, 533
successive measured injections, 500

GLUCOSE-6-PHOSPHATASE
and actinomycin, 457
assay
based on methods of Langley and Weakley, and of Ashmore, Hastings, Nesbett and Rennold, 79
and cortisone, 350
and glycogen storage disease, *327

GLUCOSE-6-PHOSPHATE, 78
assay
Gomori method, 79
and epinephrine, 362
and glucokinase, *217, *322
and glycogen synthetase, *443, *443, *443, *443, *548

GLUTAMINE
and diet and tolbutamide, 17

GLUTATHIONE
and cobalt, 405
insulin
reduction, 226
transhydrogenase, 226, 253

GLYCEROL
and nicotinic acid, *553
and norepinephrine, 298
production under anaerobic conditions, *436
release in diabetic tissues, *100

GLYCOGEN
deposition in beta cells, 60
experimental production, 606-608
and insulin assay, 622
in muscle and liver, after fracture, *557
storage disease, *325, *327
and stress, 83, *550
synthesis from glucose, *216
utilization in anaerobic turtle heart, *107

GLYCOGENESIS
and glycogen storage disease, *327

GLYCOSURIA
and epinephrine, 194
and growth hormone, 123
and hydrocortisone, 383
and ketonuria, 49
oral glucose tolerance test, *101
and pregnancy, 92, 379
and pyruvate and lactate excretion, *211
renal, *660
after stress, 83-86

GOLDMANN APPLANATION TONOMETER, 162

GOOUT
and glucose, *554

GROWTH HORMONE, 651-654
and amino acids, *445
assay specificity, 355
and beta cell vacuolization, 60
and blood glucose, 355-361
deficiency, *441
and glucagon, 565
and glucuronic acid pathway, *557
and hypoglycemia, 200, *555
immunoassay, *553
two antibody system, 5, *556
and insulin, *329, *546
antagonism, 363
and nitrogen retention, 457
and retinopathy, 122-126
secretion, *550
in urine, *214

GROWTH HORMONE DIABETES, *217

H

HAMILTON MICROLITER SYRINGES, 177

HEALTH EXAMINATION SURVEY, 267

HEART
fatty acid metabolism, *323
infarction
and insulin antagonism, *108
and synalbumin antagonism, 243

HEART DISEASE
arteriosclerotic
and dietary fat, *557
and hyperlipidemia, *102
and mortality, 375

HEMASTIX, 502

HEMOCHROMATOSIS, *215
and retinopathy, 315

HEMORRHAGE
and hypoglycemia, *108
retinal, in metasomatotrophin-diabetic dog, 124

HEPATOMA, *215, *215

HEREDITY, *104, 164, *214, *438, 569
beta-cell defect, 11
fructose intolerance, 77
in Hiroshima, Japan, 487
and insulin inhibitor, *556
multifactorial, 462-471
and pancreatitis, *549
and synalbumin antagonism, 243

HEXABARBITAL, *322

HEXOKINASE
and alloxan diabetes, *329
and glucose uptake, 362
and glycogen synthesis, *217

HEXOSE
monophosphate shunt, 585-591
and serum insulin, *437

HISTAMINE
release from rabbit platelets, *662

HOFFMAN METHOD, 30, 154

HORMONES
and carbohydrate metabolism, 238
genolytic-hyperglycemic, 172
and glucose
metabolism, *442, *547
production, 350
and glycerol, 297
and insulin antagonism, 362-365
and insulin-like activity, 71
peripheral action, *100
and phospho-enolpyruvate carboxykinase, *326
and pregnancy, 93

HYDROCHLOROTHIAZIDE, 116
and glucose tolerance, 204

HYDROCORTISONE
and anti-insulin serum, 351
and glucose, *552
tolerance tests and pregnancy, 383-386

HYDRONEPHROSIS, *557

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
March-April, 115-224

May-June, 225-338
July-August, 339-450

September-October, 451-562
November-December, 563-676

SUBJECT INDEX 1964

P-HYDROXYMERCURIBENZOATE,
*328
and palmitate incorporation, 184

HYFLO SUPER CEL, 177

HYPERCHOLESTEROLEMIA
and atherosclerosis, *105
and nicotinic acid, 568, 605

HYPERCHYLOMICRONEMIA, 294

HYPERGLUCAGONEMIA
and starvation, 566

HYPERGLYCEMIA
and adrenal steroid production, *101
in alloxan and antiserum diabetic rats, 80
and barbiturates and sulfapyrazine, *327
and benzothiadiazines, 115-121, 203-204, *328
and obesity, *328
and cobalt, 405
and cortisone, 55
and diabetes mellitus, 92
diazoxide-induced, 408, 639-644, *658
and tolbutamide, *445
epinephrine-induced, *551
and estrogens, 380
and exercise, 38
glucose-induced
and plasma-insulin response, *321
and glycogen, 194
in hypothermic rats, *103
and insulogenic reserve, 6-12
and norepinephrine, 521
and steroids, 133
and tolbutamide, 6-12

HYPERGLYCERIDEMIA
and carbohydrates, 426, *551

HYPERINSULINEMIA, 9
and glucose, 226
and narcolepsy, *326

HYPERKETONEMIA
and norepinephrine, 522

HYPERLIPEMIA
and arteriosclerosis, *101
carbohydrate-induced, *662
and pregnancy and ketosis, *554
and sulfonylureas, *555

HYPERPHAGIA, *103

HYPERTENSION
and fetal size, 94
and glucose tolerance, 294

HYPERTHYROIDISM
and carbohydrate tolerance, 194
and peripheral glucose metabolism, *547

HYPERTRIGLYCERIDEMIA
and carbohydrate intake, 87
and cardiovascular disease, *102
and coronary occlusion, *105

HYPOLYCEMIA
and adrenocortical hyperfunction, 47
and alcohol, *102
and carbohydrate metabolism, *437
and crystalline beef insulin, 27
and deamidated porcine insulin, 146
and emaciation, *215
ethanol-induced, *546
fatal postallopan, 49
and fructose, 77
and fructosuria, *105
and glucagon, *555
hydrochloride injections, 137
and growth hormone, 200, 357, *555
deficiency, *441
and hepatoma, *212
and hypoproteinemia, *329
and insulin, 46, *215, *548, 602
human and animal, 135-143
insulin-induced, *105, 169, 645-648
adrenal cortical response, *439
and epinephrine secretion, *321
and islet cell adenoma, *217
and ketones, *441, *658
leucine-induced, *106, *323, *440,
531
and blood glucose, *213, *326
and oral hypoglycemic drugs, *550
leucine-sensitive, *658
and leukemia, *103
and neoplasia, *555
and norepinephrine, *439
phloridzin-induced, 565
and retroperitoneal fibrosarcoma, *657
and sarcoma, *659
and spinal shock in rats, *108
and sulfonylureas, *547, *548
and tolbutamide, 31, *101
and Laennec's cirrhosis, *437
and tumors, nonpancreatic, *323
and zinc glucagon, *439

HYPOLYCEMIC AGENTS
and pregnancy, *99

HYPOPHYSECTOMY
and acromegaly, *216
and benzothiadiazines, 115, 641
and blood glucose after insulin, *551
and diabetic retinopathy, *442
and diazoxide, 411
and glucose phosphorylation, 350
and growth hormone, *445
and insulin, 352, *445, 457
-like activity, 256, *439
and insulinase activity, 226
and metasomatotrophin-diabetic dog,
123
and retinal metabolism, *213
and tumors, and growth hormone, 357

HYPOPITUITARISM
and growth hormone, *550
postpartum, 169

HYPOTENSION
and hypoglycemia, *108
postural, 310

HYPOTHALAMUS
and epinephrine and insulin, 199
and pituitary prolactin, *444

HYPOTHYROIDISM
and sugar tolerance, 194

I

IMMUNOELECTROPHORESIS, 580

INFANTS

big, and maternal chylomicron count,
291-296
carbohydrate
metabolism, *437
reserves, *444
determination of ketone bodies, *442
disaccharide intolerance, *321
and fasting insulin-like activity levels,
510
and fecal sugar, *324
glucose and galactose, *214
hypoglycemia
and human growth hormone, *555
and zinc glucagon, *439
and insulin antibodies, *327
islet cell hyperplasia, 91
and maternal diabetes, *105
and congenital malformations, *215,
*554
and perinatal mortality, 92, *554
premature, and glucagon feeding, *104
D-xylose absorption, *326

INSULIN

and acidosis, *327
and adipose tissue, 423
response, *105
and albumin, *108
and alcohol hypoglycemia, *103
and amino-aciduria, 20
and aniline hydroxylation, *322
antagonism, 251, *329
and cardiac infarction, *108
and plasma protein, 94
antibodies, *106, 135, 151
placental transfer, *441
and pregnancy, *327
and anti-insulin serum, *556
assay
Hales and Randle double antibody,
177
rat hemidiaphragm, 25, 622-633
two antibody method, *552
Yallow and Berson method, 388
"atypical" and "bound," 255
beta chain
and albumin, 245, 253
synthesis, *438
binding
measurement by Skom and Talmage
method, 24
and requirements, 637
bovine
molecule, 136
resistance, *102, 136

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

SUBJECT INDEX 1964

and carbohydrates, *324
 and cerebellar stimulation, *439
 and cobalt, 405
 complexes, 253
 crystalline, 136, *555
 and free fatty acids, *212
 and glycosuria, 49
 crystalline beef, 177
 and antibodies, 22, 144
 crystalline pork
 and blood glucose, 24
 and diet, *436
 dosage, and antibodies, 250
 and dumping reaction, *662
 and embryonic development, 527
 and enzyme activity, *555
 and fasting blood glucose, 179, *552
 and fatty acids, *320, *550
 free, 600-605
 free and bound, 231
 and fructose metabolism, *326
 and glucagon, 565
 and glycerol, 298
 separation, 387-394
 and glucocorticoids, 349-354
 and glucose, *215
 -adenosine triphosphate phosphotransferases, *443
 metabolism, 532-540
 tolerance test, *211
 utilization, 206
 and glucose C-14 incorporation, *658
 and glucuronic acid, *553
 and glutamic-oxalacetic transaminase, 78
 and glutamine synthetase activity, *438
 and glycerol, 298, *550
 and growth hormone, *546, *550
 and guinea pig anti-insulin serum, 532
 and histamine release, *662
 hormonal antagonists, 362-365
 human
 and animal, 135-143
 and beef-pork glucagon, 388
 crystallization, *441
 and hypoglycemia, *105, *439, 645-648
 after hypophysectomy, *551
 immunassay
 and bioassay, 189
 in children, 177-181
 and prediabetes, 190
 two antibody system, 1-5, *324, 579-584
 inhibitor, and heredity, *556
 intravenous tolerance test
 and blood potassium and phosphate, *101
 in islet cell tumor, *662
 Isophane, *657
 and lactic acid, 615-621
 Lente, *323, *553, *555
 and leucine-induced hypoglycemia, *323
 and leucocyte metabolism, *323

-like activity
 assay of Martin, Renold, and Dagenais, 510
 and diazoxide, 640
 and dietary sucrose, *547
 and lipolytic activity, *104, 297-302
 in liver perfusion in rats, *100
 and menstruation, 634-638
 metabolism, 225-229, 451-461
 molecular weight, 231
 and myasthenia gravis, *214
 nongranular, in fetal islet development, 75
 and norepinephrine, 298
 normal homeostasis, 260
 NPH, *555
 and P-32 orthophosphate, 612
 and pancreatectomy, 37
 pancreatic in New Zealand obese mice, *661
 and phenethylbiguanide, *547
 and plasma
 acid-ethanol extracts, *320
 protein-binding, and norethynodrel, 381
 porcine, *102, 148
 dealaninated, 136, 144
 and pregnancy, 260-267, 396, 634-638
 Protamine Zinc, 409, *555
 and alloxan-diabetic rats, 455
 and fetuses of white rats, 530
 and glycosuria, 49
 hypothalamic-hypophyseal adaptation, *439
 and pregnancy, 44-48
 and protein
 metabolism, 451-461
 synthesis, *551
 and pseudo hypoglycemic reactions, *548
 and pyruvic acid, 615-621
 and rabbit anti-beef insulin serum, 22-29
 radioiodine-labeled, *100
 Regular, *214, *215, 458, *657
 removal rate from circulation, 227
 requirements
 and chronic insulin resistance, 398
 and pregnancy, 92, 396
 resistance, 135, 144-152
 and acanthosis nigricans, 395-399
 and achrestic diabetes, *440
 and chronic diabetes, *213
 glucose-fatty acid cycle, 427
 secretion
 intestinal factor, *660
 and nervous system, 201
 Semilente, *323, *555
 sensitivity, 144
 in adrenocortical insufficiency, 168-176
 and serum
 alkaline phosphatase, *104
 lipids, *327
 shock therapy, *322
 and starvation, *108

synalbumin antagonism, 241-246
 synthesis of A- and B-chains, 339-348
 therapy indications, 473
 and thiazide, *443
 and tolbutamide, *99, 238, 255
 "typical" and "atypical," 232, 248
 Ultralente, *323, *555
 and hepatic glucose, 41
 and pancreatectomy, 37
 Zinc
 in metasomatotrophin-diabetic dog, 123

INSULIN-I-131
 disappearance, *657
 and insulin degradation, 248
 retention in liver, 226
 and two antibody immunoassay studies, 1-5, 178, *324, 580

INSULINASE, 226, 247
 and tumors, *659

INSULOGENIC INDEX, 9

INTELLIGENCE QUOTIENTS
 and juvenile diabetes, 303

INTERNATIONAL DIABETES FEDERATION, FIFTH CONGRESS, 109, 330, 665
 Banting medals, 665
 program of symposia, 219
 tribute to Dr. Charles H. Best, 669

IODOACETAMIDE
 and palmitate incorporation, 184

ISLETS OF LANGERHANS
 and adenohypophyseal hormones, 200
 and anti-insulin serum, *436
 and diazoxide, 119
 hydropic degeneration, 60
 and monoamines, *323
 and trichlormethiazide, 119

ISOMALTASE
 deficiency, *99

ISOPROPYL METHOXAMINE, 409

ISOPROTERENOL
 and free fatty acid release, *440

ISRAEL
 and diabetic Yemenites, 275

J

JAPAN
 Hiroshima University Diabetes Clinic, 485-491
 obesity and diabetes, 426

K

KETOACIDOSIS
 and adult-onset and juvenile diabetes, 11

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
 March-April, 115-224

May-June, 225-338
 July-August, 339-450

September-October, 451-562
 November-December, 563-676

46
339-348

5
248

tic dog,
y stud-
80

FED-
CON-
669

4

s, 200

9

linic,

etes,

and diabetic pregnancy, 92
and plasma potassium levels, *217

KETONES
and cortisol, *99
and diet, *99
and fatty acids, 596
and glucagon, *551
and glucose utilization, *658
and hypoglycemia, *441
new method for determination, *442
and norepinephrine, 519
and pancreatectomy, 38
Rothera's test, 122

KETONURIA
in antiserum-diabetic rats, 79
and glycosuria, 49
and growth hormone, 123

KETOSIS
and fasting, *212
and glycogen deposits, 607
in Hiroshima, Japan, 487
and pregnancy and hyperlipidemia, *554

KETOSTIX, 502

KIDNEY
in alloxan-diabetic hamsters, 50
Autotechnicon processing, 49
Bowman's capsule and glomerulosclerosis, 51
cortical necrosis, and pregnancy, *327
in nondiabetic animals, 50
papillary necrosis, *104
phenolsulfonphthalein test, 94

KIMMELSTIEL-WILSON LESIONS, 315, *322, *658

L

LACTIC DEHYDROGENASE
assay based on Wroblewski and LaDue method, 79

LAENNEC'S CIRRHOSIS, *437

LEUCINE
and capillary blood sugar, *550
and hypoglycemia, *106, *323, *326, *440, 531
protein incorporation, 455

LEUCOCYTES
cell concentration and metabolism, *323

LEUKEMIA
and glucose, *103

LINOLEATE-1-C-14, 183

LIPEMIA
and caloric intake, 426
carbohydrate-induced, *662
and carbutamide, 123

LIPIDS
and P-amino-salicylate, *102
and atherosclerosis, *105, 182, 205
and carbohydrates, 292, *661
and carbutamide, *327
and chlorpropamide, *657
in experimental arterial disease, 82
after fasting, *214
in lipoprotein fractions, 155
metabolism
and blood, 592-599
and cortisol, *99
patterns among Yemeneite Jews, 268, 273-277
radioactivity
incorporation, *320
and Packard Tricarb automatic liquid scintillation counter, 183

LIPOLYSIS
and hormones, *442
and insulin, 297-302

LIPOPROTEIN
and pregnancy, 153

LIVER
and adrenocortical insufficiency, 174
albumin synthesis, 20
in alloxan and antiserum diabetic rats, 81
and chlorpropamide, *659
disease
and fructose, *104
and intravenous sodium tolbutamide test, 33
fatty acid uptake, *320
fructokinase activity, 77
and glucose
and ketones, *441
output inhibition, 201
phosphorylation, *322
glucose C-14 incorporation, *658
glucose-6-phosphatase activity, 78
glycogen
and diazoxide, 412, 643
after tibia fracture, *557

and insulin
activity, 226, 234
conversion, *100
degradation, 263
microsomes, and drug metabolism, *322
necrosis and diet, 202
and phospho-enolpyruvate carboxykinase, *326, 350
potassium release, *322
pyridine nucleotides, *440

LYSINE
and tolbutamide, 17

M

MALNUTRITION
and insulin sensitivity, 174
and tolbutamide, *437

MANNOHEPTULOSE, 204

MANNOSE, *328
and pancreatic stimulation, *325

MARTIN AND RENOLD SYSTEM, 145

MELLITURIA
and disaccharide intolerance in infants, *321

MESTRANOL, 380

METABOLISM
of adipose tissue, *436
carbohydrate
and alcohol hypoglycemia, *102
and benzothiadiazines, *328
and diazoxide, 408-418
and dumping reaction, *662
and gingival tenderness, *212
and hormones, 238
and hyperglyceridemia, *551
and hypoglycemia, *437
and intravenous glucose tolerance test, *216
and ketoses, 180
and lipemia, *662
and neurologic complications, *322
and norethynodrel and mestranol, 380
and obesity, 286
and phenethylbiguanide, *217
and pregnancy, 261
and stress, 92
and thalidomide, *212
and thiazide diuretics, *103
and thyrotoxicosis, 182
cerebral, and coma, *322
drug, enzyme activity, *322
fatty acids, *323, *325
forearm, and insulin, *216, *557
fructose, *105
galactose, in infants, *214
glucose
and cortisol, *106
and fasting, *441
and fixed insulin, *100
and hyperglycemic hyponatremia, *329
and insulin, *325
and isoproterenol and DCB, *440
and tris (hydroxymethyl) aminomethane, *320
insulin, 225-229
of isolated fat cells, *442
of leucocytes, *323
lipid, and insulin, 351
and nutritional requirements, 207
and obesity during starvation, *327
and permeability of mesothelium and endothelium, *437
and phospho-enolpyruvate carboxykinase, *326
protein
and insulin, 451-461
and sulfonylureas, 14-20
pyruvate, *438

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
March-April, 115-224

May-June, 225-338
July-August, 339-450

September-October, 451-562
November-December, 563-676

SUBJECT INDEX 1964

tryptophan, *106
and vitamin B₆ deficiency, *106, *549

METALS
sulfide-silver reaction, 400

METFORMIN
and acetohexamide, *660

METHIONINE
and diet and tolbutamide, 17

METOPIRONE, *659

MICROANGIOPATHY, 90-91, 420-423, *546

MICROSCOPY
electron
of capillaries, *108, *444, 483
and glycogenization, *217
of islet cell adenomas, *214
and microangiopathy, 90
and renal biopsies, *322, *660
fluorescence
of beta cells, *323
of kidney, and glucose tolerance, *107
light
and renal biopsies, *322
of pancreatic tissue, 61
of rat fetus, 72

MICROSOMES
and leucine incorporation, 455

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY, *108

MITOCHONDRIA, DIABETIC, *660
and oxidative phosphorylation, 454

MORTALITY, *104, 373-377, 464
by age, color, and sex, 29
of alloxan-diabetic rats, *107
and amputations, *550
infant, 91, *439
and insulin-treated rats, 45
perinatal
and chlorpropamide, *325
and prediabetes, *99, 291
principal causes, 376
statistics, 312-314, 373-377

MULTIPARITY
and glucose tolerance, 292

MUSCLE
basement membrane abnormalities, 91
gastrocnemius
and action potential, 481
and pentose uptake, 41
and glucose phosphorylation, 349
and glycogen after tibia fracture, *557
proteins
and carbon dioxide fixation, *108
skeletal
and tris (hydroxymethyl) aminomethane, *320

MYASTHENIA GRAVIS
and insulin and potassium, *214

MYOCARDIUM
infarcts, and high fat diets, 43, 70

MYOPATHY, DIABETIC, 483

N

NARCOLEPSY
and hyperinsulinism, *326

NARCOTICS
and pancreatic cell vacuolization, 68

NATIONAL RESEARCH COUNCIL
chemicals in food production, report on, 21

NECROBOSIS LIPOIDICA DIABETICORUM OF THE SCALP, *548

NEPHRECTOMY
and diazoxide, 410

NEPHROPATHY
in childhood, *107
and glomerulosclerosis, 52

NEPHROPATHY, DIABETIC, *322
and congenital malformations, *554
among Yemenite Jews, 270

NEPHROSIS
glycogen, experimental, 606

NERVOUS SYSTEM
peripheral, 307-311
vagus, and insulin, 201

NEUROPATHY, 480
autonomic, 308
in Hiroshima, Japan, 487
and pancreatectomy, *658
peripheral, in nondiabetics, 368
and thalidomide, *212

NEW YORK DIABETES ASSOCIATION
Award Essays, 423
symposium on insulin antagonists, 225-259, 339-365

NEW YORKERS
and serum cholesterol, *107

NITROGEN
metabolism, and cortisol, *99
nonprotein, and tolbutamide, 20

NOREpinephrine
and free fatty acids, 518
and glycerol, 298
and hypoglycemia, *439

NORETHYNODREL, 378

NUCLEOTIDES

uridine, from uracil, *445

NUTRITION
and biochemical lesions, 207
fetal and carbohydrates, 47
and triglyceride levels, *100

O

OBESITY, *103
and atherosclerosis, 427
and benzothiadiazines, *328
and glucose tolerance, 293, *556
and free fatty acids, 286-290
and gold thioglucose, 226
and growth hormone, 359
in Hiroshima, Japan, 487, 518
and hyperketonemia, 519
and insulin
antagonism, 242, 248
-like activity, 512
responsiveness, 151
and intravenous sodium tolbutamide test, 33
in Japanese diabetics, 423
and ketonemia, 525
and metabolic changes, *320
and narcolepsy, *326
pregnancy, and steroid glucose tolerance tests, 572
and starvation, and metabolism, *327
and steroid-tolbutamide test, 131
and uric acid excretion, *321

ORAL HYPOGLYCEMIC AGENTS, *108, 473
See also Sulfonylureas
acetohexamide, *440
and anaerobic glycolysis, *213
and failures, 476
and leucine-induced hypoglycemia, *550
and plasma triglycerides, 87-89

ORTHOPHOSPHATE
organ distribution, 609-614

OVULATORY SUPPRESSANT
and glucose tolerance, 378-382

OXYGEN
and glucagon, *551

P

PACKARD AUTOGAMMA SPECTROMETER 410A, 2

PALMITATE
metabolism, and fasting, *441

PALMITATE-C-14, 183, *323, *328

PANCREAS
A cells
and growth hormone diabetes, *217

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

SUBJECT INDEX 1964

beta cells
 in alloxanized rabbits, 56
 destruction, 60
 in diabetic dogs, 60-70
 in fetal islets of rats, 71
 inherited defect, 11
 carcinoma, *660
 and catecholamines, *323
 and diazoxide hyperglycemia, 410
 extracts
 acid-alcohol method of Best, et al.,
 Kenny modification, 387
 and antiserum, 26
 and hyperglycemia, 194
 insulin
 and clinical diabetes, 181
 content in lyophilized tissue, 74
 and glucagon identification, 389
 producing capacity, and sodium tolbutamide test, 34
 release, 233
 secretion during pregnancy, 93
 insulinoma, *660
 islets
 in alloxanized rabbits, 56
 and cobalt concentration, 400-407
 dissection, *325
 in fetus, 47
 and leucine, *550
 necrosis, *553
 tests
 sodium tolbutamide, 34
 steroid tolbutamide, 127-134
 transplanted, and islet cell function, *442
 and tryptamines, *323

PANCREATECTOMY
 and blood glucose, 37-43
 and diazoxide, 410, 642
 and exercise, *325
 and glomerulosclerosis, *658
 and glucose, 500-508
 and insulin
 antagonist, 252
 -like activity, 256
 requirements, 135
 sensitivity, *551
 and metabolic studies, 78
 and oxidative phosphorylation, 454
 and pancreas implantation, *442
 partial
 and growth hormone administration, 60

PANCREATITIS, *437, *657
 and diabetic coma, *437
 and heredity, *549
 and intravenous tolbutamide test, *100
 and microangiopathies, *658
 and visceral lesions, *658

PARATHYROID GLANDS, *325

PENTOSES
 and glucose metabolism, *445
 in resting gastrocnemius muscle, 41

PEPTIDES
 insulinase-inhibitory activity, 227
 synthesis, 342, *438

PHENETHYLBIGUANIDE
 and carbohydrate metabolism, *217
 and fat tissue activity, *547

PHENFORMIN, *436, 473
 and fasting blood glucose, *552

PHENMETRAZINE
 and fatty acids, *106

PHENOBARBITAL
 and hyperglycemia, *327

PHLORIDZIN
 hypoglycemia, 565
 and sodium transport, *661

PHOSPHATE
 transport and sodium, *103

PHOSPHO-ENOLPYRUVATE CARBOXYKINASE, *326

PHOSPHOLIPIDS
 synthesis in aorta, 182-188, 205

PHOSPHORUS
 Bartlett method modification, 182
 and radioactive orthophosphate, 609-614

PHOSPHORYLASE
 and stress, *550

PITUITARY GLAND
 and carbohydrate metabolism, 457
 glycogen content, *550
 and growth, 651-654
 and insulin antagonism, 363
 and prolactin, *444
 radiosurgery, *105

PLACENTA
 and estriol, 94
 and insulin
 antibodies, *327
 -binding antibodies, *441
 circulating, 93
 degradation, 226
 impermeability, 264
 and lipid mobilization, 424, *546
 and synalbumin antagonism, 243

PLASMA
 and antiserum, 27
 corticosteroids
 and diazoxide, 641
 corticosterone, and epinephrine, *439
 fatty acids
 and fasting, *214
 in metasomatotrophin-diabetic dog, 123
 free fatty acids, *100
 Dole method, 287
 and glucose, *326
 and insulin, *212, 600-605

and lactic acid, *549
 and norepinephrine, *325
 uptake by rat liver, *320
 growth hormone, and blood glucose, 355-361

inhibitor
 and two antibody immunoassay, 579-584

insulin
 activity, Vallance-Owen technic, 7
 antagonism, 242, 251
 assay in children, 177
 bound, and Dowex cationic exchange resin column, 254
 -like activity
 and acid-alcohol extraction, *320
 and epinephrine, *551
 fasting levels, 510
 and insulin resistance, 397
 and pregnancy, 264
 recovery, 4
 lactate, and cystic fibrosis, *554
 lipids and diet, *438
 triglycerides
 by method of von Handel et al., 87
 and two antibody insulin assay, 2, *552

PLETHYSMOGRAPHY, 367, 480

POLYCYTHEMIA, *215

POLYNEUROPATHY, DIABETIC, 308

POLYTHIAZIDE, 116
 and insulin antibodies, *103

POLYURIA
 in children, *216
 and growth hormone, 123

POMPE'S DISEASE, *325

POTASSIUM
 and benzothiadiazines, 204
 chloride, and diazoxide hyperglycemia, 641
 and epinephrine, *322
 and glucagon, *322
 and insulin, *557
 and ketoacidosis, *217
 and myasthenia gravis, *214
 supplements, and hydrochlorothiazide, 116
 transport and sodium, *103

PREDIABETES
 and benzothiadiazines, 115
 and detectable insulin, 190
 and glucocorticoids, 350
 and insulin
 antagonism, 242
 and glucose infusion, *321
 and nephropathy in childhood, *107
 and perinatal mortality, 291
 and pre-beta-lipoproteins, 154
 and pregnancy, 92, *99, *105, 192
 tests, 34
 treatment, 192

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

SUBJECT INDEX 1964

PREDNISOLONE
and glucose tolerance in pregnancy, 382, 572

PREGNANCY
and benzothiadiazines, 115
and chlorothiazide, *439
and chlorpropamide, *325
and glucose tolerance, 93, 281, 291, *326
false positive tests, 383-386
and hyperlipemia, *554
and insulin, 44-48
antibodies, *327
degradation, 226
homeostasis, 260-267
and ketosis, *554
and lipid mobilization, 425, *546
and norethynodrel with mestranol, 379
and oral glucose tolerance, 279-285
and pre-beta-lipoprotein, 153-160
and prednisolone glucose tolerance test, 382, 572-578
and sodium tolbutamide, 527-531
and tolbutamide, 261

PREGNANCY, DIABETIC, 91-94, *100
and fetal survival, *439
and insulin, 634-638
requirements, 262
management, *105, *213, *217
and pre-beta-lipoproteins, 153-160
and renal cortical necrosis, *327
and tolbutamide response, 34

PROPYLTHIOURACIL, 409

PROTEINS
and amino acids, *445
degradation, 226
insulin-binding, 634-638
metabolism
and insulin, 451-461
and pyruvate, 78
and nerve diseases, 311
synthesis, 339, *552
and anaerobiosis, 453

PROTEINURIA, 480
and basement membrane changes, *322
in Hiroshima, Japan, 487

PUBLIC FORUMS COMMITTEE, 491

PUBLIC MEDICAL FORUMS, IN NIAGARA FALLS, 354

PUROMYCIN, *445, 455

PYELITIS
and diabetic pregnancy, 94

PYELONEPHRITIS, *104
and glomerulosclerosis, 52

PYREX HYDROSOL MICRO ANALYSIS FILTER HOLDERS, 177

PYRUVATE
tolerance tests, *552

PYRUVATE-I-C-14, *438

R

RADICULOPATHY, DIABETIC, 307

RENAL DIABETES
congenital tubular dysplasia, *660

RESERPINE
and diazoxide, 409

RETINA
anaerobic glycolysis, *213
and protein synthesis, 458

RETINOPATHY
in metasomatotrophin-diabetic dog, 122
and pancreatectomy, *658
and pancreatic disease, 315

RETINOPATHY, DIABETIC, *104, *444, 480
and P-amino-salicylate, *102
and anabolic steroids, *556
and cholesterol, 275
and congenital malformations, *554
exudates, *213
fluorescein studies, *554
in Hiroshima, Japan, 487
and hypophysectomy, *442
and rheumatoid arthritis, *554
among Yemenite Jews, 270

RHEUMATOID ARTHRITIS
and norethynodrel with mestranol, 381

S

SALICYLATES, *104

SALIVA
and blood group substances, 164

SARCOMA
and hypoglycemia, *659

SCIOTZ TONOMETER, 162

SEROTONIN, *324
and dumping reaction, *662

SERUM
albumin, and diet, 15
anti-insulin, 22
and carbon dioxide fixation, *108
and free and complex insulin, 231
and glucose metabolism, 532-540
and glycerol, 299
and hepatic enzyme activities, 78-82, *556
and insulin-like activity, 71
and islets of Langerhans, *436
and liver phospho-enolpyruvate carboxylase activity, 350
bilirubin levels in premature infants, *104

cholesterol
Colman chemical methods, 273
and nicotinic acid, 605
among Trappist monks, 296, 517
and vascular disease, 425
among Yemenite Jews, 273
enzymes, *553
insulin
antagonism, 144
anti-human in assays, 177
-binding capacity, 24
free and bound, *661
and hexose, *437
-like activity, 190, 509-517
and glucose tolerance test, *211
and islet cell tumors, *444
suppressible and nonsuppressible, *324
and thiazides, *443
typical and atypical, *107
in New Zealand obese mice, *661

lipids
and carbohydrates, *661
and carbutamide, *327
and diet, 425-428
Kien-gravimetric-method, 273
and portacaval transposition, *556
and vascular disease, *436

lipoproteins, 153-160

potassium, and hypoglycemia, *101

protein, 459
-bound carbohydrates, *657
and diet, 15
insulin-binding, 634-638
and tolbutamide, 15, *661

tolbutamide
lability tests, 20
modification of Toolan-Wagner method, 31

triglycerides, and atherosclerosis, 425

uric acid, and glucose, *554

SEX
and blood groups, 167

SHEEHAN'S SYNDROME, 169

SHOCK
spinal and hypoglycemia, *108

SKIN
resistance, and free fatty acids, 600-605

SKOM AND TALMAGE TECHNIC, 24

SODIUM
chloride, and myocardial infarcts, 70
and glucose transport, *103, *661
liothyronine, *320
tolbutamide
oral and intravenous tests, 31
and pancreatic carcinoma, 33
and pregnant albino rats, 527-531

SOUTH AFRICAN MEDICAL JOURNAL
diabetes symposium, 113

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

March-April, 115-224

May-June, 225-338

July-August, 339-450

September-October, 451-562

November-December, 563-676

SUBJECT INDEX 1964

SPINCO ANALYTROL, 387

SPINCO ULTRACENTRIFUGE. *See*
Ultracentrifugation

STARVATION

and glucagon, *108
and glucokinase, *217, *444
and glucose, *437
and growth hormone, 358
and insulin, *108
and phenethylbiguanide, *217
and pyridine nucleotides, *440
and renal concentrating ability, *329
and uric acid excretion, *321

STATISTICS, 312-314, 468, 472-478,
485-491, 622-633

mortality, 373, 464

STEATORRHEA, DIABETIC, *557

STEROIDS

adrenal
and hypophysectomy, *101
and synalbumin antagonist, 242
and alloxanized rabbits, 55
anabolic, and blood sugar, *556
and carbohydrate synthesis, *444
and glucose
tolerance in pregnancy, 382, 572
utilization, 350
subdiabetogenic doses, 56
and tolbutamide test, 127-134

STILLBIRTHS

and glucose tolerance, 293

STRESS

and diabetes onset, *108
and glycogen, *550
glycosuria, in Chinese hamsters, 83-86
and insulogenic reserve, 6-12

SUCRASE

intestinal deficiency, *99

SUCROSE

and metabolism, *657

SULFAPYRAZINE

and hyperglycemia, *327

SULFISOXAZOLE, *659

SULFONYLUREAS, *436, *445

and elderly patients, *102
failures, 474, *548
and fasting blood glucose, *552
and free fatty acids, *441
and hepatic detoxication, *553
and hyperlipemia, *555
and hypoglycemia, *547, *548
and insulin, *557
and juvenile diabetics, *213
and plasma triglycerides, 87
and protein metabolism, 14-20

SURGERY

amputation, *546, *550

SYNALBUMIN

insulin antagonism, 241-246, 253

T

TEMPERATURE

and mortality in alloxan-diabetic rats,
*107

TES-TAPE, 291

THALIDOMIDE

and blood pyruvic acid, *212

THAM. *See* Tris (hydroxymethyl) amine, *320

THIAZIDES

and carbohydrate tolerance, *211
and insulin, *557
-like activity, *443

THROMBOSIS

and dietary fats, 43

THYMUS

atrophy, *325

THYROID

hormones
anti-insulin activity, 362
and propylthiouracil, 411

THYROIDECTOMY

and insulinase activity, 226

THYROTOXICOSIS

and intravenous sodium tolbutamide
test, 33
and steroid-tolbutamide test, 131

THYROXIN

anti-insulin activity, 362
and mestranol, 381
protein-bound in pregnancy, 93

TISSUE

adipose
and fatty acids, *320, 407, *553
free, *216, 351, *549
glucose uptake, *100, *105, 350
and glucose C-14, 509-517, *658
glucuronic acid pathway, *556
and insulin, 144, 231, 423, *661
-inhibitory albumin, *546
lipoprotein lipase, *104
metabolism, *324, *436, *550
fructose, *326
glucose, *440
and peptides, *438
synthesis, *551
and phenethylbiguanide, *547
and plasma insulin, 248
and serum insulin-like activity, *444
aortic
and glucose metabolism, *329
arterial wall
and phospholipid synthesis, 205
capillary basement membranes
thickening, 371

conceptus

and insulin degradation, 263

elastic

and insulin distribution, *557

epididymal fat

and glycerol, 297
insulin-like activity, 71, *324
Martin and Renold assay, 145

and plasma insulin-like activity, 515

forearm

metabolism, *657
and radioiodine-labeled insulin, *100

hepatic

fatty acid synthesis, *443

insulin-inactivating and degrading,

225

lipids

and palmitate, *438

lyophilized pancreatic, 72

muscle

and insulin, 231

myocardial lipoprotein lipase, *104

pancreatic

densitometry, 388

and insulin, 23, *324

and cobalt, 400-407

and glucagon, *107

parametrial fat pad

perfusion technic, *107

rat diaphragm

and glucose uptake, 251

insulin assay, 241

retinal

metabolism, *213

microscopy of, *108

TOBACCO

and plasma free fatty acids, *326

TOLAZAMIDE

comparison with tolbutamide, *216

TOLBUTAMIDE, 30-36, 409, 473, *547,
*548

and alkaline phosphatase, *104

and benzothiadiazines, 116, 204, 409

and blood glucose, *551

and blood sugar, *661

comparison with tolazamide, *216

and cystic fibrosis, *554

and diazoxide hyperglycemia, *445,
640

and dumping reaction, *662

and free fatty acids, 191

and glucose, 6-12, 379

and glucuronic acid, *553

and growth hormone, *550

and hyperglycemic stress, 6-12

and hyperlipemia, *555

and hypoglycemia, *101, *551

and diazoxide, *328

and Laennec's cirrhosis, *437

and insulin

free and bound, 255

-regulatory mechanisms, *99, 238

and insulinoma, *321

intravenous test, 131, 191

and pancreatitis, *100

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

SUBJECT INDEX 1964

and lactic acid, 615-621
and leucine metabolism, *550
and litter size, 528
and lysine, 17
and obesity, *320
and pancytopenia, *212
and plasma triglycerides, 88
and pregnancy, 261
and pyruvic acid, 615-621
and serum
 alkaline phosphatase, *104
 insulin-like activity, *551
 proteins, *661
and skeletal development, 529
and steroid test, 127-134
teratogenic effect, absence of, *105
and weight, *661

TOOLAN-WAGNER METHOD, 31

TRANSAMINASES
glutamic-oxaloacetic
 and antiserum diabetic enzyme values, 79
 and tolbutamide, *104
glutamic-pyruvic
 assay, 79
 and tolbutamide, *104

TRAPPIST MONKS, 296, 517

TRIACINOLONE
and carbohydrate synthesis, *444

TRICHLORMETHIAZIDE
diabetogenic activity, 203
and hyperglycemia, 115, 408

TRIGLYCERIDES
and atherosclerosis, 425
and catecholamines, 363
fasting and postprandial levels, *100
in lipoproteins, 155
and pregnancy, 291

TRIS (HYDROXYMETHYL) AMINO-METHANE, *320

TRYPSIN
and visceral lesions, *658

TRYPTAMINE
in beta cells, *323

TRYPTOPHAN
hypoglycemia and insulinase-inhibitory actions, 227
metabolism, *106

TUMORS. See also specific types
endocrine, *444
and hypoglycemia, *214, *555, *659
insulin
 -like activity, *323
 -producing, and hypoglycemia, 531
 -secreting, *657
islet cell
 and glucagon, 566
 and hypoglycemia, *217
 and insulin, *444, 531, *662

pituitary
 and adrenalectomy, *105

TWINS, *104, *214, *325

L-TYROSINE
transport and sodium, *103

U

UDPG - ALPHA - GLUCAN TRANSGLYCOLASE, *443, *443

UDPG - GLYCOGEN TRANSGLUCOSYLASE, *442, *443

ULCER, PEPTIC
and adenoma, *328
and pancreas, *329

ULTRACENTRIFUGATION
of lipoproteins, 154
in two antibody inhibitor study, 2

UREA
and glucagon, *551

URIDINE DIPHOSPHATE GLUCOSE-GLYCOGEN GLUCOSYLTRANSFERASE
after insulin, *555

URINE
alanine, 17
amino acids
 and diet and tolbutamide, 15-17
calcium, *325
cystine, 17
epinephrine, *105, 175
free sulphate, 20
fructose, 77, *104, *105
glucose
 in alloxan-diabetic rats, 46
 creatinine determinations, 384
 and exercise, 40
 and stress, 83
 and tolazamide, *216
glucuronic acid, *553
glutamine, 17
growth hormone, *214
insulin-like activity, 397
kynurenine, *106
lactate, *211
lysine, 17
methionine, 17
nitrogen, *99
 and cortisol, *99
phenolic compounds, *553
phosphorus, *325
pyruvate, *211
sugar
 and blood glucose, 196
 and diet, 15
 and tolbutamide, 15
taurine, 17
tests, 473
 Benedict's method, 291
 for blood, 502

for glucose, 83, *101, *327, 502
for ketone bodies, 502
Nelson blood glucose adaptation, 137

for protein, 502
for sugar, *327, 606
Technicon AutoAnalyzer, 84
Tes-Tape, 291
tryptophane, 17
tyrosine, 17
uric acid, *322
xanthurenic acid, *106

URISTIX, 502, 606

V

VALLANCE-OWEN TECHNIC, 7

VASCULAR DISEASE
in Hiroshima, Japan, 487

VASCULAR SYSTEM
disease
 and mortality, 375
 and serum lipids, *436
 among Yemenite Jews, 268-272, 273-277
evaluation technics, 367

VON GIERKE'S DISEASE, 607

W

WEIGHT
adrenal
 and alloxan diabetes, *101
of diabetic Yemenite Jews, 269
gain
 and hyperglyceridemia, 427
 and tolbutamide, *661
 and glucagon, *107
in Hiroshima, Japan, 486
loss
 and benzothiadiazines, 116
 and calories, *439
 and carbohydrate-free diet, *99, *100
 and carbutamide, 123
 and metabolic changes, *320
of pup of insulin-treated rat, 45
and sodium tolbutamide tests, 33
and stress, 84
and sulfonylurea treatment, 88

Y

YALOW AND BERSON METHOD, 388

YEMENITE JEWS, 268-272, 273-277

Z

ZINC GLUCAGON, *439

ZOLLINGER - ELLISON SYNDROME, *328

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

7, 502
laptation,

AUTHOR INDEX 1964

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1964. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. The Subject Index appears on page 1.

A

Abelman, Walter H., *215
Achor, Richard W. P., *441
Ack, Marvin, 303-306
Ahrens, E. H., Jr., *551
Akre, P. R., 135-143
Albertsen, Kai, *329
Albrink, Margaret J., 425, *436
Al-Khalidi, Usama, *217
Alp, Haluk, 509-517, *546
Alpert, Samuel, *211
Altares, C. Diez, 609-614
Altman, S., 268-272, 273-277
Anderson, Charlotte M., *99
Anderson, Donald O., *216
Anderson, Gail V., 383-386
Anderson, J., *211
Anderson, John B., *102
Angel, A., *549
Anigian, Michael J., *212
Antoniades, Harry N., *99, 230-240
Arai, Y., *553
Arky, Ronald A., *102, *546
Armento, D. F., *557
Arnold, A., *556
Arnould, Yvette, *211, 532-540
Ashmore, James, *108, 297-302, 349-354,
*440, *444, *556
Ashton, W. L., *108
Auerbach, Victor H., *213
Awai, Kozi, *320, 592-599
Aydin, Abdullah, *320
Azar, Gordon J., *99, *100

B

Baens, Gloria S., *437
Bahn, Robert C., *555
Baird, C. W., *327
Baker, A. B., *215
Balcerzak, S. P., *658
Baldwin, Faye, *326, *555
Ball, Eric G., *324, *436, *550
Bally, P., *324
Bambers, G., 177-181
Barnes, P. H., *99
Barrett, James C., 144-152
Bassett, J. M., *99
Batts, Adrienne A., *324
Beardwood, D. M., *320
Beaser, Samuel B., 49-53, *436, 472-478
Beaven, D. W., *102
Becker, David J., *212
Beckett, Sibyl B., *322

C

Beerman, Herman, *546
Behar, A., *442
Bell, R. J. M., *546
Bellens, Roger, *211
Bendersky, G., *554
Benjamin, William, *320
Bennett, Leslie L., *324
Bercovici, Edwin, *546
Berge, Kenneth G., *441
Berkowitz, Donald, *100, *320
Berns, Aline W., *436, *657
Berson, Solomon A., 247-259, 355-361
Best, Charles H., 500-508
Beven, Edwin G., *549
Beyler, A. L., *556
Bierman, Edwin L., *101
Blackard, William G., 485-491, 518-526
Bleicher, Sheldon J., *102, *546
Block, M. A., *546
Bloom, Walter L., *99, *100
Blumenthal, Daniel S., *436
Blumenthal, Herman T., *214, *436,
*657
Boda, J. M., *437
Bolinger, Robert E., 87-89, 600-605,
*657
Bookman, John J., *213
Born, James L., *105
Boshell, Buris R., 144-152, *657
Bottiger, L. E., *657
Bougas, James A., *99, 230-240
Bowers, C. Y., *657
Brandt, N. J., *212
Brill, Richard, 30-36
Brinley, Marlene S., *554
Brobeck, John R., *103
Brown, David F., *100
Brown, Harold, *551
Brunjes, Shannon, *105
Brunner, D., 268-272, 273-277
Brzezinski, A., 291-296
Buchanan, James, *523
Buckle, Richard M., *212
Buckwalter, Joseph A., 164-168
Bürgi, H., *100, *324
Burns, Thomas W., *212
Buse, John, *320
Buse, Maria G., *320, *557
Butterfield, L. Joseph, *100
Butterfield, W. J. H., *100, *547, *550,
*657

C

Cahill, George F., Jr., *328, *658

Calkins, W. Graham, *437
Camerini-Davalos, Rafael, *99, 230-240,
*440
Cameron, J. Stewart, *320
Cameron, John R., *553
Campanacci, L., *659
Campbell, G. D., *325
Campbell, James, 122-126
Cantu, R. C., *321
Canzanelli, A., *443
Carlson, Lars A., *100
Carr, Lucinda, *440
Carrington, Elsie R., *100
Carruthers, Bruce, 572-578
Carson, Nina A. J., *321
Casciarano, Joseph, *437
Castelli, William P., *661
Castleman, Benjamin, *660
Cerasi, E., *321
Cervini, Grace, *211
Chapman, Irving, *212
Charbon, G. A., *100
Chazan, B. I., 291-296
Cheetham, H. D., *101
Chen, Edith T., 83-86
Cheraskin, E., *212
Cherner, Rachmel, *101
Chernick, Sidney S., *554
Cheung, Wan Ho, *212
Chick, William L., *437
Churg, Jacob, *322
Cillo, Anthony, *103
Classen, Kenneth L., *328
Cohen, A. M., *547
Cohen, Richard B., *215
Cohn, Howard J., *437
Conard, Victor, *211, 532-540
Conn, Jerome W., *323
Cooperberg, Arthur A., *438
Cornatzer, W. E., *659
Cornblath, Marvin, *437
Correa, Riet P., *547
Coskey, Richard L., *321
Cowan, J. S., 500-508
Cox, Stephen E., *212, *439
Craig, Albert B., Jr., *321
Crawford, J. D., *555
Cristofori, Fred C., *321
Crofford, O. B., *658
Crombie, D. L., *101, *547
Csapó, G., *213, *327
Csorba, Thomas R., *215
Cummins, Alvin J., *103
Cuppage, Francis E., *101
Cutler, O. E., *328

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

AUTHOR INDEX 1964

D

Dachs, Samuel, *322
 Dall, J. L. C., *547
 Danowski, T. S., 649-650
 David, Margit A., *213
 Davidson, A. I. G., *437
 Davidson, Charles S., *215
 Davis, E., 291-296
 Davis, Frank H., Jr., *442
 Davis, P. L., *553
 Davis, Thomas R. A., *107
 Dawson, John E., 527-531
 Delcher, Harry K., 645-648
 Della Porta, P., *322
 De Meutter, Roger C., 615-621
 Depocas, Florent, *547, *547
 der Kinderen, P. J., *327
 de Roeth, Andrew, Jr., *213
 Derrow, A., *443
 de Sousa, R., 191-192
 de Ulhoa Cintra, Antonio B., 169-176
 Devectorski, Miloje S., *101
 De Venanzi, F., 609-614
 de Wolfe, Victor G., *549
 Diedrich, Dennis, 600-605, *657
 Di George, Angelo M., *213
 Dimick, M. K., *551
 DiPietro, David L., *322
 Dixit, Padmakar K., 71-77
 Dixon, Robert L., *322
 Dobson, Harold L., *551
 Doisy, Richard J., *662
 Dole, Vincent P., *101
 Dolger, Henry, *213
 Dokart, Ralph E., 78-82
 Dollery, C. T., *443, *554
 Donaldson, George W., 49-53
 Dos Reis, Luciano, *658
 Dotevall, G., *102
 Dougherty, Joseph C., *217
 Doyle, A. P., *658
 Doyle, Joseph T., *100
 Drash, Allan, *658
 Dresner, Martin, *103
 Drewyer, Richard, 572-578
 Dube, Arthur H., *104
 Duncan, Gafford G., 318, *321
 Dustin, P., *108, *444

E

Eggeman, Joanne, 509-517
 Ehrentheil, Otto F., 83-86
 Ehrlich, Robert M., 177-181
 Eisentraut, Anna M., *108, 563-568
 Eliasbar, Y., 291-296
 Ellenberg, Max, *322
 Elliott, Daniel W., *214
 Elliott, Robert B., *556
 Ellis, Sydney, *322
 Ells, Joyce, *324
 Elrick, H., *553
 Elwood, Clint, *104
 Enquist, Irving F., *658
 Entmacher, Paul S., 373-377
 Esmann, Viggo, *102, *213, *322

Espinier, E. A., *102
 Esterhuizen, A. C., 387-394
 Esterley, John A., *216
 Evans, Burtis R., *548
 Evans, Gordon R., *548
 Evans, John R., *323, *438, *441
 Evans, Joseph R., *548

F

Fabrykant, Maximilian, *548, *548
 Fairhurst, Bernard J., *102
 Fajans, Stefan S., *323
 Falck, B., *323
 Falkmer, Sture, 400-407
 Faludi, Georgina, *102, *554
 Feldman, Robert, *102
 Felts, P. W., *438, *658
 Ferguson, Isabel C., *323
 Field, James B., *213, *323, *658
 Field, Richard B., *554
 Fischer, N., *321
 Fishman, Robert A., *658
 FitzGerald, M. G., *101
 Floyd, John C., Jr., *323
 Flynn, William R., *108
 Ford, J., *553
 Ford, J. D., *104, *214, *324
 Forero, J., 609-614
 Fosbrooke, A. S., 153-160
 Foster, David O., *326
 Fouts, James R., *322
 Franckson, J. R. Marcel, *211, 532-540
 Frankel, Marcel, *214
 Fraser, G. R., *438
 Fraser, Russell, *107, *443, *554
 Frawley, Thomas F., *101, *106
 Freeman, Mavis, *99
 Freinkel, Norbert, *102, 260-267, *546
 Freis, Edward D., *438
 Frenkel, H. S., 492-499
 Frerichs, Heiko, *324
 Friedman, Daniel L., *548
 Froesch, E. R., *100, *324
 Frøland, A., *212
 Fuhrman, Frederick A., *103
 Fuhrman, Geraldine J., *103
 Fukuchi, Sotaro, *439
 Fukuda, Kouhei, *438
 Fuld, Jeanne, *440

G

Gaethe, George, *548
 Galloway, J. A., 135-143
 Gann, Donald S., *329, *329
 Ganong, W. F., *621
 Garratt, C. J., *100
 Gaulden, E. C., *549
 Gehrk, Charles W., *212
 Gelfand, Maxwell L., *548
 Geller, Jack, *214
 Gellhorn, Alfred, *320
 Gerber, Bernard C., *549
 Gershberg, Herbert, 378-382, *441
 Gershoff, Stanley N., *549

Gerstein, Mordecai M., *662
 Gibbons, G. E., 366-372
 Glassman, Sol, *100
 Glick, Seymour M., 355-361
 Goetz, Frederick C., *324, *327, 395-399
 Gold, Martin, *549
 Goldenberg, Julio, *103
 Goldfen, A., *321
 Golding, Michael R., *658
 Goldman, Jack K., *658
 Goldner, Martin G., *546
 Gorczyca, Robert, *103
 Gordis, Enoch, *101
 Gottsagen, Warren L., *107
 Grahame, G. R., *552
 Grann, V., *659
 Greenberg, Beryl Z., *324
 Greenberg, E., *442
 Greenberg, Sigmund R., *103
 Greenwood, F. C., *550
 Greider, Marie H., *214
 Grishman, Edith, *322
 Grodsky, Gerold M., *102, *324
 Groen, J. J., 492-499
 Groppé, Carl W., Jr., *101
 Gryboski, Joyce D., *216
 Guiso, G. F., *659
 Gulbenkian, A., 408-418
 Gullixson, K. S., *321
 Gunning, Barbara, *439
 Cylling, Martti, *659

H

Hall, J. Denny, *328
 Hamilton, C. L., *103
 Hamilton, Henry E., *659
 Hamilton, J. G., *657
 Hammarstrand, Kent, *320
 Hanrahan, James B., *103
 Hansson, C. G., *325
 Harland, W. Arthur, *438
 Harris, Thomas S., *445
 Harris, Virginia L., 6-13
 Harrison, H. E., *439
 Harrison, Harold E., *103
 Harrison, Helen C., *103
 Hart, Larry G., *322
 Harter, John G., *103
 Harvald, Bent, *104, *104, *214, *325
 Hauge, M., *104, *214, *325
 Haunz, E. A., *659
 Hausler, H. R., 122-126
 Haworth, J. C., *104, *214, *324
 Heald, Felix P., *556
 Heggestad, Carl B., 71-77
 Hegsted, D. Mark, *549
 Heiskala, Heikki, *659
 Hellem, H. K., *442
 Heller, Nathan, *215
 Hellerstrom, C., *325
 Hellman, B., *107, *323
 Henderson, Alan M., *555
 Henmeman, D. H., *442
 Hennes, Allen R., *320, 592-599
 Henry, J. Ben, Jr., 606-608

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

March-April, 115-224

May-June, 225-338

July-August, 339-450

September-October, 451-562

November-December, 563-676

AUTHOR INDEX 1964

Herrick, C. N., *439
 Herring, Betty, *323
 Herzog, Walter, *327
 Heslin, A. Sandra, *100
 Hetenyi, G., Jr., 500-508
 Hill, D. W., *554
 Hinkle, Lawrence E., Jr., *106
 Hirata, Y., *214
 Hlad, C. J., Jr., *553
 Hodge, J. V., *554
 Hoekstra, M. H., *100
 Holdsworth, C. D., *660
 Hollenberg, C. H., *549
 Holmstrom, A., *657
 Holton, Sandra, *214
 Honig, Carl R., *321
 Huber, Agnes M., *549
 Huijning, F., *325, *327
 Hulse, Mildred, 378-382
 Humphries, Alfred W., *549
 Hunter, W. M., *550
 Hurley, Nancy, *556

I

Ide, Takehiko, *439, *551
 Imaichi, Kunitaro, *214
 Issekutz, B., Jr., *325, *549

J

Jackson, W. P. U., *325
 Jacobowitz, D., *550
 Jacobs, Norman M., *444
 Jacobsen, Carl F., *104
 Janda, V., 479-484
 Jandl, James H., *215
 Jarrett, R. J., *550
 Javier, Zenaida, 378-382
 Jeffrey, W. L., *658
 Jensen, H. J., *102
 Jezeckova, Z., *106
 Jinks, Robert, *441
 Johns, Varner J., *105
 Johnson, Phyllis, *323
 Jones, Douglas J., *557
 Jones, H. Walter, Jr., *215
 Jungas, Robert L., *436, *550

K

Kahil, Michel E., *551
 Kalant, Norman, *215, *438
 Kalser, Martin H., *212, *557
 Kaneto, Akio, *439
 Karam, Edmund, *216
 Katsoyannis, Panayotis G., 339-348, *438
 Kattine, Anthony A., *107
 Kayne, Herbert L., *554
 Keating, William C., *549
 Keen, Harry, *320, *323
 Keilding, R., *104
 Kennan, A. L., *438
 Kessler, Jacques I., *104
 Khachadurian, Avedis K., *104
 Kibler, Robert F., *551

Kiernan, Owen, *217
 Kilo, Charles, 127-134, 509-517
 Kinch, R. A. H., 44-48
 King, Judith, *555
 King, Lester S., *438
 Kinsell, Laurance W., *212, *214, *439
 Kirschenfeld, J. J., *657
 Kirtley, W. R., 135-143, *326, *440
 Klayman, Joel, 161-163
 Klein, Reuben I., *437
 Klink, Douglas, 395-399
 Knittle, Jerome L., *551
 Knopf, Ralph F., *323
 Knowles, Harvey C., Jr., 315, 395-399,
 649-650
 Knutson, Folke, 400-407
 Koch, E., *551
 Koch, Mary B., 509-517
 Kock, N. G., *102
 Kohout, F. W., *102
 Koike, T. I., *551
 Kollar, Edward J., *108
 Kool, D. Schuckink, *100
 Kopetz, K., *100
 Kosaka, Kinori, *439, *551
 Kovács, K., *213
 Kozák, P., 479-484
 Krahl, M. E., *551
 Kraicer, Jacob, *439
 Krall, Leo P., *440
 Krech, Louise H., *320
 Krosnick, Arthur, 649-650
 Kumashiro, H., *553
 Kunitake, G. M., *553
 Kushner, Roger S., *439
 Kuzuya, Nobusada, *551
 Kuzuya, Takeshi, *439, *551, *552
 Kvam, Donald C., 639-644
 Kyle, G. Clayton, *105, 572-578

L

Labhart, A., *324
 Ladner, Calvin N., *439
 Lammert, Albert C., *439
 Landau, Bernard R., *326, *445
 Langdon, R. G., *557
 Langley, Paul E., *212
 Lardy, Henry A., *326
 Larmer, Joseph, *442, *443, *443, *443,
 *548
 Larsson, Yngve, *440
 Lavietes, Paul H., *436
 Lawrence, John H., *105
 Lawrence, R. D., *215
 Lazarow, Arnold, 1-5, 71-77, 433, *440,
 579-584
 Lazarus, Sydney S., 54-59, 60-70, *105,
 *217, *445
 Leak, David, *105
 Lecoco, Frank R., *552
 Lefebvre, P., *552
 LeFevre, Fay A., *549
 Lehan, P. H., *442
 Lehoczky, D., *440
 Lemli, Luc, *439
 Lemon, Calvin, *439

Leon, Nelson, 569-571
 Leonards, Jack R., *326
 Lepkovasky, S., *551
 Leppänen, V. V. E., *106
 Lerner, Philip I., *659
 Levin, B., *105
 Levine, Rachmiel, 362-365, 420-423,
 651-654
 Liugorri, G., *659
 Likimani, J. C., *107
 Lindall, Arnold W., Jr., *440
 Linfoot, John A., *105
 Lloyd, J. K., 153-160
 Lochner, J. de V., 387-395
 Locke, Simeon, 307-311, 541
 Loebl, K., 273-277
 Logothetis, John, *215
 Logothetopoulos, John, *439
 Loh, Arthur, *214
 London, Morris, *440
 Long, Charles, Jr., 127-134
 Losekoot, G., *325
 Lourie, Herbert, *104
 Love, E. J., 44-48
 Love, William C., *440
 Lowe, Irene P., 71-77
 Lozano-Castaneda, Oscar, *99, *440
 Lubash, Glenn D., *217
 Lucas, John F., Jr., *442
 Luft, R., *321, 651-654
 Lukens, F. D. W., 451-461
 Lukert, Barbara, 600-605
 Lundbaek, K., *102, *104, *213
 Luper, M., *659

M

Mabry, C. Charlton, *213, *216
 MacDonald, Richard A., *215
 MacDowell, M., *660
 Madison, Leonard L., *108, *441, *552
 Madsen, P. H., *213
 Magyar, I., *440
 Mahabir, Ram, 286-290
 Mahan, Clare M., 278-285
 Maher, R. J., *659
 Mahler, Robert, 297-302
 Maiolo, T. A., *322
 Makman, Maynard H., *660
 Malaisse, Willy, 532-540
 Maldow, Charles F., *546
 Man, Evelyn B., *436
 Manjeshwar, Rajani, *443
 Marble, Alexander, *99, 435, *440, *555
 Marinuzzi, V., *660
 Marks, B. H., *550
 Marks, Herbert H., 373-377
 Marques, M., *547
 Martin, Donald B., *660
 Martin, F. I. R., *327
 Marton, I., *440
 Marymont, Jesse H., *440
 Masoro, E. J., *443
 Matsumura, Y., *551
 Mattar, Emilio, 169-176
 Mautner, Willy, *322
 Mayer, Jean, *556

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

March-April, 115-224

May-June, 225-338

July-August, 339-450

September-October, 451-562

November-December, 563-676

AUTHOR INDEX 1964

Mazurkie, Stanley J., *99
 Mazza, R., *211
 McArthur, Lloyd G., *326, *440
 McCall, John C., *106
 McCrae, W. Morrice, *326
 McGavack, Thomas Hodge, *105
 McGuckin, Warren F., 37-43, *441
 McIntyre, Neil, *660
 McKnight, Frank G., *657
 McLaughlin, Robert J., 49-53
 McLean, Franklin C., 193-197, 198-202
 McLean, J. M., *442
 McManus, J. F., 606-608
 McMaster, Jan, *320
 McWilliams, Nancy B., *102, *324
 Meade, Robert C., *441
 Mebane, David, *441, *552
 Meinerl, Curtis, *324
 Meites, J., *444
 Melrose, A. G., *547
 Menzel, P. H., *557
 Menzinger, Guy, *320
 Messer, M., *99
 Mestman, Jorge H., 383-386
 Michaels, George D., *214, *439
 Michener, William M., *439
 Miki, Eishi, *551
 Mikkelsen, M., *212
 Miller, Harvey I., *325, *549
 Mirsky, I. Arthur, 225-229, *441
 Molliver, M., *555
 Molnar, George D., 37-43, *441, 634-638
 Monasterio, G., *660
 Montgomery, D. A. D., *660
 Moore, Richard O., *105
 Moorhouse, J. A., *216, *441, *552, *552
 Morgan, Carl R., 1-5, 579-584
 Morgan, H. E., *438
 Morgan, Jean M., *552
 Morgan, Robert E., *552
 Morris, Helen G., *553
 Morris, J. Harold, 87-89, *657
 Morris, Russell E., Jr., *553
 Morrison, E. S., *107
 Morse, William I., 286-290
 Moss, Gerald, 585-591
 Moxness, Karen E., 37-43
 Muiesan, G., *660
 Muldrey, J. E., *657
 Munroe, John F., 645-648
 Murray, Ian, *323
 Müting, Dieter, 14-21, *553
 Myers, Jack D., *551

N

Nadler, Henry L., *441
 Nakamura, R. M., *553
 Nalbandoi, A. V., *551
 Nangle, Grace, *217
 Narahara, H. T., 22-29
 Nechemias, Charles, *213
 Neely, R. A., *321
 Negri, U. V., *322
 Neiken, L., 268-272, 273-277

Nelson, Don H., 383-386
 Neumann, Lois L., *441
 Newell, John M., *661
 Newns, C. H., *216
 Nickerson, Rita J., *661
 Nieland, Michael L., *554
 Nielsen, A., *212
 Nora, James J., *553
 Nordlie, Robert C., *326
 Norris, Henry J., *553
 Numeroff, Martin, *437

O

Oberholzer, V. G., *105
 Oberlander, Lawrence K., *658
 O'Brien, Donough, *100
 Offerhaus, L., 492-499
 Oka, Martti, *106
 Okinaka, Shigeo, *439, *551
 Okun, Ronald, *328
 Oliver, J., *660
 Omori, Yoshiaki, 485-491, 518-526
 Onesti, G., *554
 Opie, Lionel H., *323, *438, *441
 Oppenheimer, Ella H., *216
 Oster, Harold L., 30-36
 Ostman, Jan, *100, *553
 O'Sullivan, John B., 278-285

P

Padova, J., *554
 Palumbo, Pasquale J., 634-638
 Pantelakis, S. N., 153-160
 Pardelli, G., *660
 Park, C. R., *658
 Parker, Frank, 182-188, 205-207
 Parker, Virgil, *106
 Parmley, William W., 115-121, *328, *328
 Patchefsky, A., *554
 Patton, Thomas B., 144-152, *662
 Paulsen, Elsa P., 161-163
 Pav, J., *106
 Pazianos, A., *442
 Pearson, Jack W., *439
 Pearson, O. H., *442
 Peden, Virginia H., *442
 Pedersen, L. Molsted, *554
 Pei, Yen Fen, *213
 Penick, S. B., *106
 Pensuwan, Suksawat, *106
 Pereira, Virgilio G., 169-176
 Peretz, W. L., *442
 Perisutti, Gladys, *441
 Perkoff, Gerald T., *106
 Perlmutter, Martin, *437
 Persson, Bengt, *440
 Petersen, Jorgen, *554
 Petersson, B., *107
 Phear, D. N., *327
 Picón-Reátegui, E., *442
 Pines, Kermit L., 423
 Plotkin, S., *216
 Poe, Robert H., *107
 Posner, Norman A., *326

Potts, G. O., *556
 Powell, Elinor D. U., *554
 Priest, R. E., 366-372
 Probst, J. G., *657
 Pupo, Armando A., 169-176, 569-571
 Purdy, R., *659
 Pyle, Hugh M., *99, 230-240

Q

Quabbe, H. J., 191-192
 Quintao, Eder R., 569-571

R

Rabinowitz, David, *216, *557
 Raiti, S., *216
 Ramseier, E. B., *324
 Rappaport, A. M., 500-508
 Rastogi, G. K., *660
 Ratner, A., *444
 Ray, B. S., *442
 Recant, Lillian, 127-134, 509-517, *546
 Reddy, William J., *103
 Reemtsma, Keith, *442
 Reeves, Robert B., *107
 Regan, T. J., *442
 Reider, J., 268-272, 273-277
 Rennie, Charles S., *216
 Renold, Albert E., 189-191, *217, *438, *444

Reyna, Leo J., 83-86
 Richardson, James, *439
 Rilliet, B., 191-192
 Ringsdorf, W. M., *212
 Robert, André, *107
 Roberts, H. J., *326
 Rodahl, K., *325
 Rodbell, Martin, *442
 Rogers, Larry A., *322
 Rogers, Robert E., *442
 Root, Howard F., 373-377
 Rosan, Robert C., *554
 Rosell-Perez, M., *442, *443, *443, *443
 Rosen, N. J., *441, *552
 Rosenbaum, Percy, *107
 Rosevear, John W., *441
 Rosella, E., *322
 Roth, C. H., *556
 Roth, Jesse, 355-361
 Rubin, Arnold D., *437
 Rupp, Joseph J., *101
 Rutstein, David D., *661

S

Safir, Aran, 161-163
 Sailer, F. X., *551
 Sak, Matthew F., 49-53
 Salas, Margarita, *216, *217
 Saldanha, P. H., 569-571
 Salzberg, Gertrude, *211
 Samaan, N., *107, *443
 Samols, Ellis, *552
 Sarcione, Edward J., *555

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114

May-June, 225-338

September-October, 451-562

March-April, 115-224

July-August, 339-450

November-December, 563-676

AUTHOR INDEX 1964

Sargeant, B. M., *657
 Sax, Sylvan M., *103
 Scherr, Lawrence, *217
 Scherrer, Joseph, *546
 Schimmelbusch, Werner, 182-188
 Schipper, Hirsch L., *661
 Schless, Guy L., 419
 Schmidt, Frank E., *442
 Schultz, Stanley G., *661
 Schumacher, L. R., *320
 Schumacher, O. Peter, *439
 Schwachman, Harry, *554
 Schwartz, Heinz, *326, *555
 Schwartz, William B., *328
 Schwarz, F., *327
 Schwarz, K., *100
 Scott, D. J., *554
 Scott, R. F., *107
 Scow, Robert O., *107, *554
 Sebus, J., *100
 Seidman, F., 408-418
 Seltzer, Holbrooke S., 6-13
 Shamma'a, Munir, *217
 Shamoian, C. A., *443
 Sharkey, Thomas P., 208-209
 Sharma, Chakravarthi, *322, *443
 Shaw, Walter N., *556, *661
 Sheets, Raymond F., *659
 Sheldon, Joanna, *662
 Shelley, Heather J., *444
 Shigeta, Yukio, 615-621
 Shipp, Joseph C., *323, *441, *555, 645-
 648
 Shnaider, José, 169-176
 Shrago, Earl, *326
 Shreeve, Walton W., 615-621
 Shuey, Eldon W., *661
 Sibay, T. M., *122-126
 Silbert, Cynthia K., *102
 Silverstein, Joseph N., *437
 Silverstein, Murray N., *555
 Silverstone, Felix A., *326
 Simpson, Nancy E., 462-471
 Singer, Adolf, *661
 Singer, David L., *102
 Singhal, R. L., *445
 Skrha, F., *106
 Slawson, Paul F., *108
 Smale, Milton, 383-386
 Smelo, Leon S., *555
 Smith, David L., 30-36
 Smith, David W., *439, *553
 Smith, Desmond F., *324
 Smith, Morton, *108
 Snegireff, Leonid, *217
 Sneyd, J. G. T., *661
 Snodgrass, G. J. A. I., *105
 Soeldner, J. Stuart, *444
 Sokal, Joseph E., *320, *555
 Soloff, Louis A., *326, *555
 Solomon, Lawrence M., *546
 Solomons, Edward, *326
 Sols, Alberto, *216, *217
 Sommers, Sheldon C., 49-53
 Sorenson, Robert L., 1-5, 579-584
 Soteres, Pete S., *657
 Soyka, L. F., *555
 Spaulding, W. B., *327

Spellacy, William N., *327
 Spitzer, John J., *549
 Spitzer, W. O., *327
 Spritz, Norton, *662
 Stafford, W. S., 297-302
 Stanley, John R., *327
 Stanton, Hubert C., 639-644
 Starr, Paul, *105
 Stein, J. H., *659
 Steinberg, J., *216, *441
 Steiner, Donald F., *555
 Steinke, Jürgen, *444
 Stenzel, Kurt H., *217
 Stephens, Ronald, 600-605
 Sterky, Göran, *439
 Sternberg, Martin S., *212
 Stevens, Charles D., *327
 Stevenson, J. A. F., 44-48
 Stimmller, L., *105
 Stimmller, Leo, *556
 Stone, Joseph E., *445
 Strandness, D. E., Jr., 366-372
 Strauss, Maurice B., 655
 Streeten, David H. P., *662
 Sullivan, John J., *104
 Sullivan, Julia C., *661
 Sullivan, M. Bruce, Jr., *662
 Sunao, Wada, 485-491
 Sutherland, Earl W., Jr., *660
 Suzuki, Kenji, *438
 Szucs, S., *327

T

Tabachnick, I. I. A., 408-418
 Tainter, M. L., *556
 Talwalker, P. K., *444
 Tarrant, M. E., 297-302
 Tauxe, W. Newton, 634-638
 Taylor, K. W., *662
 Taylor, W. Jake, *551
 Teitelbaum, A., *547
 Teitlebaum, Jacobo I., *438
 Tessler, B. B., *216
 Thomas, W. A., *107
 Thoren, Claes, *440
 Thorn, George W., *103
 Thukor, J. J., *107
 Tidball, M. E., *662
 Tilak, Manohar, *438
 Tobias, Cornelius A., *105
 Toda, Shintaro, 485-491
 Tolstrup, N., *212
 Tometsko, Andrew, *438
 Tompkins, R., *553
 Torok, Elizabeth E., 78-82
 Toussaint, D., *108, *444
 Townley, R. R. W., *99
 Tranquada, Robert E., *321
 Traylor, Frank A., *217
 Truscott, P. W., *327
 Tucker, W. Randolph, 395-399
 Turner, D. S., *660
 Turner, Malcolm E., *327
 Tygstrup, Inge, *554
 Tyler, Frank H., *106

U

Uete, Tetsuo, *444
 Underwood, Louise E., *444
 Unger, Roger H., *108, 387-394, 563-568
 Utiger, Robert D., *556

V

Vajda, Beno, *556
 Vallance-Owen, J., *108, 241-246
 Van Belle, G., 622-633
 Van Cauwenberge, H., *552
 van Creveld, S., *325, *327
 van Gool, J., *108
 van Riet, H. G., *327
 Vcella, Carl, *324
 Vecchio, Thomas J., 30-36
 Villar-Palasi, C., *442
 Viñuelo, Eladio, *216, *217
 Voigt, Gerhard E., 400-407
 Volk, Bruno W., 54-59, 60-70, *105,
 *217, *445
 von Laveran-Stiebar, Rudolf, 419

W

Waddell, William R., *556
 Wagle, Shreepad R., *108, *445, *556
 Waife, S. O., *326, *440
 Wajchenberg, Bernardo L., 169-176, 569-
 571
 Wakim, Khalil G., *555
 Walker, B. G., *327
 Walker, Robert S., *217
 Wanless, John F., *217
 Wardlaw, A. C., 622-633
 Washington, A., *555
 Waterhouse, Christine, *102
 Waters, William C., III, *328
 Watkins, David H., *217
 Watson, J. H., *556
 Weaver, Galen, *445
 Weaver, J. A., *660
 Weber, George, *445
 Weil, William B., Jr., 303-306
 Weinhouse, Sidney, *322, *443
 Weinstein, Louis, *659
 Wellmann, Klaus F., *445
 West, Donald A., 87-89
 Whichelow, Margaret J., *100, *547,
 *657
 White, James B., 639-644
 White, Joseph W., *107
 White, Kathleen, *328
 Whitehouse, F. W., *546
 Whitney, J. E., *328
 Wiederanders, Rex E., *328
 Wilensky, Allan S., 144-152
 Wilkinson, John F., *328
 Williams, Robert H., 22-29, 182-188, 205-
 207
 Williamson, John R., *217
 Wilmers, Mary J., *105
 Winegrad, Albert I., *329, *556
 Wise, B. L., *321

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114
 March-April, 115-224

May-June, 225-338
 July-August, 339-450

September-October, 451-562
 November-December, 563-676

AUTHOR INDEX 1964

Wolff, Frederick W., 115-121, 203-204,
*328, *328, *445, *557, *658
Wolff, O. H., 153-160
Wood, Francis C., Jr., *328, *555
Woolfolk, Donald, *662
Worthington, W. Curtis, Jr., *557
Wray, James B., *557
Wrenshall, G. A., 500-508
Wright, F. E., *328
Wright, Hastings K., *329, *329
Wright, Peter H., 78-82
Wruble, Lawrence D., *557
Wybregt, Susan H., *437

Y

Yalcin, Saliha, *329, 572-578
Yalow, Rosalyn S., 247-259, 355-361
Yamakido, Michiro, 485-491
Yerganian, George, 83-86
Yerry, Roger, *106
Younathan, Ezzat S., *445
Young, Frank G., *329
Young, Jess R., *549
Young, Marjorie A. C., *217
Yudkin, John, *557
Yunis, Edmond, *553

Z

Zacharewicz, Francis, *106
Zacks, Sumner I., 90
Zahnd, G. R., 189-191
Zalme, Elisabeth, 395-399
Zalusky, Ralph, *661
Zatuchni, J., *557
Zierler, Kenneth L., *216, *557
Zollinger, Robert M., *214, *329
Zweifach, Benjamin W., *437

Boo

MAN

DIABETES: VOLUME 13 (1964) PAGE NUMBERS BY ISSUE

January-February, 1-114	May-June, 225-338	September-October, 451-562
March-April, 115-224	July-August, 339-450	November-December, 563-676

Reviewers

The Editors of *Diabetes: The Journal of the American Diabetes Association* are grateful to the following persons who reviewed books during the year 1964; or who, although not members of the Editorial Board, evaluated scientific contributions to the Journal.

BOOKS

Deaconess Maude Behrman, Atlantic City
George F. Cahill, Jr., M.D., Needham, Mass.
Thaddeus S. Danowski, M.D., Pittsburgh
Maximilian Fabrykant, M.D., New York
Frederick C. Goetz, M.D., Minneapolis
Martin G. Goldner, M.D., Brooklyn
Irving Graef, M.D., New York
Leo P. Krall, M.D., Boston
Irving H. Leopold, M.D., New York
Gerson T. Lesser, M.D., New York
Henry E. Marks, M.D., New York

Milton Mendlowitz, M.D., New York
Hiromichi T. Narahara, M.D., St. Louis
Vaun A. Newill, M.D., Cleveland
Herbert Pollack, M.D., Leesburg, Va.
Lillian Recant, M.D., St. Louis
Elmer L. Severinghaus, M.D., New York
Otakar V. Sirek, M.D., Ph.D., Toronto
Randall G. Sprague, M.D., Rochester, Minn.
Jurgen Steinke, M.D., Boston
Cecil Striker, M.D., Cincinnati
Sigmund L. Wilens, M.D., New York

MANUSCRIPTS

Glenn Bartsch, Sc.D., Cleveland
Göran C. H. Bauer, M.D., New York
Bernard Becker, M.D., St. Louis
Solomon A. Berson, M.D., New York
J. M. B. Bloodworth, Jr., M.D., Madison, Wis.
William W. Bromer, Ph.D., Indianapolis
Josiah Brown, M.D., Los Angeles
George F. Cahill, Jr., M.D., Needham, Mass.
Reginald E. Haist, M.D., Toronto
Murray Heimberg, M.D., Nashville
B. L. Horecker, Ph.D., Philadelphia
Maurice E. Krahf, Ph.D., Chicago
Paul E. Lacy, M.D., Ph.D., St. Louis

Franklin C. McLean, M.D., Chicago
James V. Neel, M.D., Ann Arbor
Vaun A. Newill, M.D., Cleveland
Albert E. Renold, M.D., Geneva, Switzerland
Paul D. Saville, M.D., New York
Martin Silberberg, M.D., St. Louis
Marvin D. Siperstein, M.D., Dallas
Thomas G. Skillman, M.D., Omaha
Randall G. Sprague, M.D., Rochester, Minn.
Sidney Weinhouse, Ph.D., Philadelphia
Kelly M. West, M.D., Oklahoma City
Arne N. Wick, Ph.D., San Diego
S. L. Wilens, M.D., New York

Memoranda

